AU2003273553B2 - Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same - Google Patents
Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same Download PDFInfo
- Publication number
- AU2003273553B2 AU2003273553B2 AU2003273553A AU2003273553A AU2003273553B2 AU 2003273553 B2 AU2003273553 B2 AU 2003273553B2 AU 2003273553 A AU2003273553 A AU 2003273553A AU 2003273553 A AU2003273553 A AU 2003273553A AU 2003273553 B2 AU2003273553 B2 AU 2003273553B2
- Authority
- AU
- Australia
- Prior art keywords
- hydrogen
- methyl
- chloro
- disorders
- benzimidazolylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 title claims description 68
- 238000000034 method Methods 0.000 title claims description 48
- 229930192474 thiophene Natural products 0.000 title claims description 21
- 150000003577 thiophenes Chemical class 0.000 title description 5
- 239000003153 chemical reaction reagent Substances 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 127
- 229910052739 hydrogen Inorganic materials 0.000 claims description 73
- 239000001257 hydrogen Substances 0.000 claims description 64
- 238000011282 treatment Methods 0.000 claims description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 49
- 125000004432 carbon atom Chemical group C* 0.000 claims description 45
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 37
- 208000035475 disorder Diseases 0.000 claims description 35
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 33
- -1 trans-R Chemical compound 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 25
- 150000002431 hydrogen Chemical group 0.000 claims description 19
- 229910052731 fluorine Inorganic materials 0.000 claims description 18
- 238000011321 prophylaxis Methods 0.000 claims description 18
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 230000001154 acute effect Effects 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 16
- 239000000460 chlorine Substances 0.000 claims description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 16
- 125000001424 substituent group Chemical group 0.000 claims description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 13
- 206010012601 diabetes mellitus Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 13
- 206010019280 Heart failures Diseases 0.000 claims description 12
- 210000000056 organ Anatomy 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 230000006378 damage Effects 0.000 claims description 11
- 201000001320 Atherosclerosis Diseases 0.000 claims description 10
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 10
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 10
- 229910052740 iodine Inorganic materials 0.000 claims description 10
- 230000000302 ischemic effect Effects 0.000 claims description 10
- 239000001301 oxygen Substances 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 208000023504 respiratory system disease Diseases 0.000 claims description 10
- 125000003342 alkenyl group Chemical group 0.000 claims description 9
- 125000004946 alkenylalkyl group Chemical group 0.000 claims description 9
- 210000003169 central nervous system Anatomy 0.000 claims description 9
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 8
- 206010048554 Endothelial dysfunction Diseases 0.000 claims description 8
- 208000020832 chronic kidney disease Diseases 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 230000008694 endothelial dysfunction Effects 0.000 claims description 8
- 230000010410 reperfusion Effects 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 7
- 125000002947 alkylene group Chemical group 0.000 claims description 7
- 230000001472 cytotoxic effect Effects 0.000 claims description 7
- 239000011737 fluorine Substances 0.000 claims description 7
- 210000002307 prostate Anatomy 0.000 claims description 7
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- 206010041235 Snoring Diseases 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 231100000433 cytotoxic Toxicity 0.000 claims description 6
- 210000001519 tissue Anatomy 0.000 claims description 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 5
- 208000007536 Thrombosis Diseases 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims description 5
- 230000003176 fibrotic effect Effects 0.000 claims description 5
- 201000002859 sleep apnea Diseases 0.000 claims description 5
- 238000011477 surgical intervention Methods 0.000 claims description 5
- 208000030090 Acute Disease Diseases 0.000 claims description 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims description 4
- 206010020880 Hypertrophy Diseases 0.000 claims description 4
- 206010022562 Intermittent claudication Diseases 0.000 claims description 4
- 208000033626 Renal failure acute Diseases 0.000 claims description 4
- 201000011040 acute kidney failure Diseases 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 230000006870 function Effects 0.000 claims description 4
- 206010020718 hyperplasia Diseases 0.000 claims description 4
- 208000021156 intermittent vascular claudication Diseases 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 230000035939 shock Effects 0.000 claims description 4
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims description 3
- 125000006532 (C3-C5) alkyl group Chemical group 0.000 claims description 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- 229910020587 CmF2m+1 Inorganic materials 0.000 claims description 3
- 208000007530 Essential hypertension Diseases 0.000 claims description 3
- 208000007101 Muscle Cramp Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000028017 Psychotic disease Diseases 0.000 claims description 3
- 208000005392 Spasm Diseases 0.000 claims description 3
- 230000009692 acute damage Effects 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 206010003119 arrhythmia Diseases 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000009693 chronic damage Effects 0.000 claims description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 201000004792 malaria Diseases 0.000 claims description 3
- 238000003860 storage Methods 0.000 claims description 3
- 238000002054 transplantation Methods 0.000 claims description 3
- OUJWXEIDCSOWLT-UHFFFAOYSA-N n-(2-chloro-4-methylthiophen-3-yl)-n-methyl-1h-benzimidazol-2-amine Chemical compound N=1C2=CC=CC=C2NC=1N(C)C=1C(C)=CSC=1Cl OUJWXEIDCSOWLT-UHFFFAOYSA-N 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 230000006793 arrhythmia Effects 0.000 claims 2
- 208000037976 chronic inflammation Diseases 0.000 claims 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 2
- 244000078703 ectoparasite Species 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 230000003871 intestinal function Effects 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 238000004321 preservation Methods 0.000 claims 2
- 210000001835 viscera Anatomy 0.000 claims 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 claims 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 327
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 139
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 136
- 239000000203 mixture Substances 0.000 description 107
- 239000000047 product Substances 0.000 description 75
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 69
- 239000000243 solution Substances 0.000 description 68
- 229960000583 acetic acid Drugs 0.000 description 67
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 62
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 62
- 239000012362 glacial acetic acid Substances 0.000 description 62
- 239000002904 solvent Substances 0.000 description 59
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 57
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 52
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 49
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 47
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 45
- 239000007787 solid Substances 0.000 description 44
- 239000003112 inhibitor Substances 0.000 description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 40
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 40
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 39
- 230000002829 reductive effect Effects 0.000 description 37
- 102100022897 Sodium/hydrogen exchanger 10 Human genes 0.000 description 34
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 31
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 30
- 239000012071 phase Substances 0.000 description 29
- 239000000741 silica gel Substances 0.000 description 28
- 229910002027 silica gel Inorganic materials 0.000 description 28
- 239000012074 organic phase Substances 0.000 description 26
- 230000002265 prevention Effects 0.000 description 25
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 21
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 20
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 20
- 235000019341 magnesium sulphate Nutrition 0.000 description 20
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 20
- OQEAUWWCSIBKKC-UHFFFAOYSA-N 3-isothiocyanato-4-methylthiophene Chemical compound CC1=CSC=C1N=C=S OQEAUWWCSIBKKC-UHFFFAOYSA-N 0.000 description 19
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 18
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000013078 crystal Substances 0.000 description 16
- KQDJZZWCYTXUDE-UHFFFAOYSA-N hydron;thiophene;chloride Chemical compound Cl.C=1C=CSC=1 KQDJZZWCYTXUDE-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 15
- 239000002244 precipitate Substances 0.000 description 15
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 14
- 239000011541 reaction mixture Substances 0.000 description 14
- 108091006649 SLC9A3 Proteins 0.000 description 12
- 102100030375 Sodium/hydrogen exchanger 3 Human genes 0.000 description 12
- 230000009471 action Effects 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 12
- 235000019253 formic acid Nutrition 0.000 description 12
- 239000007789 gas Substances 0.000 description 12
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- 238000010626 work up procedure Methods 0.000 description 11
- YZDSXIIHWIWUPH-UHFFFAOYSA-N 3-chloro-4-isothiocyanatothiophene Chemical compound ClC1=CSC=C1N=C=S YZDSXIIHWIWUPH-UHFFFAOYSA-N 0.000 description 10
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 238000002425 crystallisation Methods 0.000 description 9
- 230000008025 crystallization Effects 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000005526 G1 to G0 transition Effects 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- 229910021529 ammonia Inorganic materials 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 238000004237 preparative chromatography Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 229910052708 sodium Inorganic materials 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 230000002349 favourable effect Effects 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 150000003254 radicals Chemical class 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 5
- 206010061216 Infarction Diseases 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- 239000008346 aqueous phase Substances 0.000 description 5
- 238000004821 distillation Methods 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000007574 infarction Effects 0.000 description 5
- 208000028867 ischemia Diseases 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 108091006650 SLC9A2 Proteins 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- 102100030382 Sodium/hydrogen exchanger 2 Human genes 0.000 description 4
- 230000003178 anti-diabetic effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical class [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- OGSUWVLDPAKUDB-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-6-amine Chemical compound NC1CCCCC11OCCO1 OGSUWVLDPAKUDB-UHFFFAOYSA-N 0.000 description 3
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 3
- 229960000571 acetazolamide Drugs 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical class OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 239000003472 antidiabetic agent Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 238000013375 chromatographic separation Methods 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- VVGYLIJOPUUXJN-UHFFFAOYSA-N methyl 3-acetamidothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1NC(C)=O VVGYLIJOPUUXJN-UHFFFAOYSA-N 0.000 description 3
- XFZRGYXMGOYGIC-UHFFFAOYSA-N n-(4-chlorothiophen-3-yl)-5,6-difluoro-1h-benzimidazol-2-amine Chemical compound N1C=2C=C(F)C(F)=CC=2N=C1NC1=CSC=C1Cl XFZRGYXMGOYGIC-UHFFFAOYSA-N 0.000 description 3
- WDIJVZXCWRMRIY-UHFFFAOYSA-N n-(4-chlorothiophen-3-yl)-6-fluoro-1h-benzimidazol-2-amine Chemical compound N=1C2=CC(F)=CC=C2NC=1NC1=CSC=C1Cl WDIJVZXCWRMRIY-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 244000045947 parasite Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- HNGBYETZGCADEX-UHFFFAOYSA-N 1-(1,4-dioxaspiro[4.5]decan-6-yl)-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)NC1C2(OCCO2)CCCC1 HNGBYETZGCADEX-UHFFFAOYSA-N 0.000 description 2
- INCCIFKMFDDPAF-UHFFFAOYSA-N 1-(2-amino-3,4,5,6-tetrafluorophenyl)-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)NC1=C(N)C(F)=C(F)C(F)=C1F INCCIFKMFDDPAF-UHFFFAOYSA-N 0.000 description 2
- QBPJXEKTOLWCHB-UHFFFAOYSA-N 1-(2-amino-3,5-difluorophenyl)-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)NC1=CC(F)=CC(F)=C1N QBPJXEKTOLWCHB-UHFFFAOYSA-N 0.000 description 2
- SGHVNACWJKHOEF-UHFFFAOYSA-N 1-(2-amino-3-chlorophenyl)-3-(4-chlorothiophen-3-yl)thiourea Chemical compound NC1=C(Cl)C=CC=C1NC(=S)NC1=CSC=C1Cl SGHVNACWJKHOEF-UHFFFAOYSA-N 0.000 description 2
- NBFRXJUGPIIWFE-UHFFFAOYSA-N 1-(2-amino-3-chlorophenyl)-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)NC1=CC=CC(Cl)=C1N NBFRXJUGPIIWFE-UHFFFAOYSA-N 0.000 description 2
- JXRFENJVLQQGHL-UHFFFAOYSA-N 1-(2-amino-3-fluorophenyl)-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)NC1=CC=CC(F)=C1N JXRFENJVLQQGHL-UHFFFAOYSA-N 0.000 description 2
- VWGRBUDPUSCUKN-UHFFFAOYSA-N 1-(2-amino-3-methoxyphenyl)-3-(4-methylthiophen-3-yl)thiourea Chemical compound COC1=CC=CC(NC(=S)NC=2C(=CSC=2)C)=C1N VWGRBUDPUSCUKN-UHFFFAOYSA-N 0.000 description 2
- ILZJYZUHWSFHRI-UHFFFAOYSA-N 1-(2-amino-3-methylphenyl)-3-(4-chlorothiophen-3-yl)thiourea Chemical compound CC1=CC=CC(NC(=S)NC=2C(=CSC=2)Cl)=C1N ILZJYZUHWSFHRI-UHFFFAOYSA-N 0.000 description 2
- YLZDIWOHYBOAAS-UHFFFAOYSA-N 1-(2-amino-3-methylphenyl)-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)NC1=CC=CC(C)=C1N YLZDIWOHYBOAAS-UHFFFAOYSA-N 0.000 description 2
- ZKNJYCSKJCBCHB-UHFFFAOYSA-N 1-(2-amino-4,5-dichlorophenyl)-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)NC1=CC(Cl)=C(Cl)C=C1N ZKNJYCSKJCBCHB-UHFFFAOYSA-N 0.000 description 2
- SIXFKRSDPVDHBP-UHFFFAOYSA-N 1-(2-amino-4-fluorophenyl)-3-(4-chlorothiophen-3-yl)thiourea Chemical compound NC1=CC(F)=CC=C1NC(=S)NC1=CSC=C1Cl SIXFKRSDPVDHBP-UHFFFAOYSA-N 0.000 description 2
- VDWKFZQABQBSIP-UHFFFAOYSA-N 1-(2-amino-4-methoxyphenyl)-3-(4-methylthiophen-3-yl)thiourea Chemical compound NC1=CC(OC)=CC=C1NC(=S)NC1=CSC=C1C VDWKFZQABQBSIP-UHFFFAOYSA-N 0.000 description 2
- NMTPGPSKXLPJTL-UHFFFAOYSA-N 1-(2-amino-5-fluorophenyl)-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)NC1=CC(F)=CC=C1N NMTPGPSKXLPJTL-UHFFFAOYSA-N 0.000 description 2
- YNAKNGZDQQDLNS-UHFFFAOYSA-N 1-(2-aminophenyl)-3-(4-chlorothiophen-3-yl)thiourea Chemical compound NC1=CC=CC=C1NC(=S)NC1=CSC=C1Cl YNAKNGZDQQDLNS-UHFFFAOYSA-N 0.000 description 2
- ATVQFPJPHSOCSM-UHFFFAOYSA-N 1-(2-aminophenyl)-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)NC1=CC=CC=C1N ATVQFPJPHSOCSM-UHFFFAOYSA-N 0.000 description 2
- CWNLCWLYOVOEAK-UHFFFAOYSA-N 1-(2-chloro-4-methylthiophen-3-yl)-2-(1,4-dioxaspiro[4.5]decan-6-yl)guanidine Chemical compound CC1=CSC(Cl)=C1NC(=N)NC1C2(OCCO2)CCCC1 CWNLCWLYOVOEAK-UHFFFAOYSA-N 0.000 description 2
- VQXIJGHSVCAADA-UHFFFAOYSA-N 1-(2-chloro-4-methylthiophen-3-yl)-4,5,6,7-tetrahydrobenzimidazol-2-amine;hydrochloride Chemical compound Cl.CC1=CSC(Cl)=C1N1C(CCCC2)=C2N=C1N VQXIJGHSVCAADA-UHFFFAOYSA-N 0.000 description 2
- SYNKHMGQFZFAER-NXEZZACHSA-N 1-[(1r,2r)-2-aminocyclohexyl]-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)N[C@H]1[C@H](N)CCCC1 SYNKHMGQFZFAER-NXEZZACHSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- VNKXPANHAIBZNE-UHFFFAOYSA-N 1-[2-amino-3-chloro-5-(trifluoromethyl)phenyl]-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)NC1=CC(C(F)(F)F)=CC(Cl)=C1N VNKXPANHAIBZNE-UHFFFAOYSA-N 0.000 description 2
- RYHUIFWGVKANNW-UHFFFAOYSA-N 2-(1,4-dioxaspiro[4.5]decan-6-yl)-1-(4-methylthiophen-3-yl)guanidine Chemical compound CC1=CSC=C1NC(=N)NC1C2(OCCO2)CCCC1 RYHUIFWGVKANNW-UHFFFAOYSA-N 0.000 description 2
- VTXXEHOHKKZQIB-UHFFFAOYSA-N 2-amino-3-[(4-methylthiophen-3-yl)carbamothioylamino]benzoic acid Chemical compound CC1=CSC=C1NC(=S)NC1=CC=CC(C(O)=O)=C1N VTXXEHOHKKZQIB-UHFFFAOYSA-N 0.000 description 2
- CHXZRHMQQRUVHF-UHFFFAOYSA-N 2-hex-5-en-1,3-diynyl-5-prop-1-ynylthiophene Chemical compound CC#CC1=CC=C(C#CC#CC=C)S1 CHXZRHMQQRUVHF-UHFFFAOYSA-N 0.000 description 2
- SAIXZIVDXDTYCH-UHFFFAOYSA-N 3-chlorobenzene-1,2-diamine Chemical compound NC1=CC=CC(Cl)=C1N SAIXZIVDXDTYCH-UHFFFAOYSA-N 0.000 description 2
- OJSCBKGRGMBEEW-UHFFFAOYSA-N 3-fluorobenzene-1,2-diamine Chemical compound NC1=CC=CC(F)=C1N OJSCBKGRGMBEEW-UHFFFAOYSA-N 0.000 description 2
- BFLWXPJTAKXXKT-UHFFFAOYSA-N 3-methoxybenzene-1,2-diamine Chemical compound COC1=CC=CC(N)=C1N BFLWXPJTAKXXKT-UHFFFAOYSA-N 0.000 description 2
- XCJMRYCTWBDPQJ-UHFFFAOYSA-N 4-chlorothiophen-3-amine Chemical compound NC1=CSC=C1Cl XCJMRYCTWBDPQJ-UHFFFAOYSA-N 0.000 description 2
- KWEWNOOZQVJONF-UHFFFAOYSA-N 4-fluorobenzene-1,2-diamine Chemical compound NC1=CC=C(F)C=C1N KWEWNOOZQVJONF-UHFFFAOYSA-N 0.000 description 2
- UDNCRSHPCPEMEY-UHFFFAOYSA-N 5,6-difluoro-n-(4-methylthiophen-3-yl)-1h-benzimidazol-2-amine;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CC1=CSC=C1NC1=NC2=CC(F)=C(F)C=C2N1 UDNCRSHPCPEMEY-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- 102000003846 Carbonic anhydrases Human genes 0.000 description 2
- 108090000209 Carbonic anhydrases Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 108091006513 Chloride/bicarbonate exchangers Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- QENGPZGAWFQWCZ-UHFFFAOYSA-N Methylthiophene Natural products CC=1C=CSC=1 QENGPZGAWFQWCZ-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 108091006647 SLC9A1 Proteins 0.000 description 2
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 229940127282 angiotensin receptor antagonist Drugs 0.000 description 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000036523 atherogenesis Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 229960004580 glibenclamide Drugs 0.000 description 2
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
- 229960004346 glimepiride Drugs 0.000 description 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 150000003840 hydrochlorides Chemical class 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 230000000055 hyoplipidemic effect Effects 0.000 description 2
- 208000021822 hypotensive Diseases 0.000 description 2
- 230000007954 hypoxia Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 208000003243 intestinal obstruction Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- ACBQXSGPYIMTDS-UHFFFAOYSA-N methyl 3-acetamido-4,5-dichlorothiophene-2-carboxylate Chemical compound COC(=O)C=1SC(Cl)=C(Cl)C=1NC(C)=O ACBQXSGPYIMTDS-UHFFFAOYSA-N 0.000 description 2
- FGBJNRLHSOQZMV-UHFFFAOYSA-N methyl 3-acetamido-4-chlorothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=C(Cl)C=1NC(C)=O FGBJNRLHSOQZMV-UHFFFAOYSA-N 0.000 description 2
- UGZKUKBGCABYDB-UHFFFAOYSA-N methyl 3-amino-4-chlorothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=C(Cl)C=1N UGZKUKBGCABYDB-UHFFFAOYSA-N 0.000 description 2
- LOXXINLYDQYAIQ-UHFFFAOYSA-N methyl n'-(1,4-dioxaspiro[4.5]decan-6-yl)-n-(4-methylthiophen-3-yl)carbamimidothioate Chemical compound C=1SC=C(C)C=1N=C(SC)NC1CCCCC11OCCO1 LOXXINLYDQYAIQ-UHFFFAOYSA-N 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- PZMINJKSDFCOPE-UHFFFAOYSA-N n-(2,4-dichlorothiophen-3-yl)-5,6-difluoro-1h-benzimidazol-2-amine;hydrochloride Chemical compound Cl.N1C=2C=C(F)C(F)=CC=2N=C1NC=1C(Cl)=CSC=1Cl PZMINJKSDFCOPE-UHFFFAOYSA-N 0.000 description 2
- GNVYFAZMAYAXKS-UHFFFAOYSA-N n-(2,4-dichlorothiophen-3-yl)-6-fluoro-1h-benzimidazol-2-amine;hydrochloride Chemical compound Cl.N=1C2=CC(F)=CC=C2NC=1NC=1C(Cl)=CSC=1Cl GNVYFAZMAYAXKS-UHFFFAOYSA-N 0.000 description 2
- HPDCPNVGZZXIOG-UHFFFAOYSA-N n-(2-bromo-4-methylthiophen-3-yl)-6-fluoro-1h-benzimidazol-2-amine Chemical compound CC1=CSC(Br)=C1NC1=NC2=CC(F)=CC=C2N1 HPDCPNVGZZXIOG-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 201000008383 nephritis Diseases 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 239000012429 reaction media Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- GLQWRXYOTXRDNH-UHFFFAOYSA-N thiophen-2-amine Chemical class NC1=CC=CS1 GLQWRXYOTXRDNH-UHFFFAOYSA-N 0.000 description 2
- 230000002885 thrombogenetic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- SSJXIUAHEKJCMH-LWOQYNTDSA-N (1r)-cyclohexane-1,2-diamine Chemical compound NC1CCCC[C@H]1N SSJXIUAHEKJCMH-LWOQYNTDSA-N 0.000 description 1
- SSJXIUAHEKJCMH-PHDIDXHHSA-N (1r,2r)-cyclohexane-1,2-diamine Chemical compound N[C@@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-PHDIDXHHSA-N 0.000 description 1
- SSJXIUAHEKJCMH-OLQVQODUSA-N (1s,2r)-cyclohexane-1,2-diamine Chemical compound N[C@H]1CCCC[C@H]1N SSJXIUAHEKJCMH-OLQVQODUSA-N 0.000 description 1
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
- FKTXDTWDCPTPHK-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical group FC(F)(F)[C](F)C(F)(F)F FKTXDTWDCPTPHK-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- SSNCMIDZGFCTST-UHFFFAOYSA-N 1,3-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=C(F)C=CC=C1F SSNCMIDZGFCTST-UHFFFAOYSA-N 0.000 description 1
- YHRCETZIQZWDHW-UHFFFAOYSA-N 1-(2-amino-4,5-difluorophenyl)-3-(4-chlorothiophen-3-yl)thiourea Chemical compound NC1=CC(F)=C(F)C=C1NC(=S)NC1=CSC=C1Cl YHRCETZIQZWDHW-UHFFFAOYSA-N 0.000 description 1
- SYNKHMGQFZFAER-QVDQXJPCSA-N 1-[(1r)-2-aminocyclohexyl]-3-(4-methylthiophen-3-yl)thiourea Chemical compound CC1=CSC=C1NC(=S)N[C@H]1C(N)CCCC1 SYNKHMGQFZFAER-QVDQXJPCSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- KKTUQAYCCLMNOA-UHFFFAOYSA-N 2,3-diaminobenzoic acid Chemical compound NC1=CC=CC(C(O)=O)=C1N KKTUQAYCCLMNOA-UHFFFAOYSA-N 0.000 description 1
- IQKRFOZZASFSRW-UHFFFAOYSA-N 2-(1,4-dioxaspiro[4.5]decan-6-yl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCCCC11OCCO1 IQKRFOZZASFSRW-UHFFFAOYSA-N 0.000 description 1
- FUJSJWRORKKPAI-UHFFFAOYSA-N 2-(2,4-dichlorophenoxy)acetyl chloride Chemical compound ClC(=O)COC1=CC=C(Cl)C=C1Cl FUJSJWRORKKPAI-UHFFFAOYSA-N 0.000 description 1
- MJPKHSSFTWJJSX-UHFFFAOYSA-N 2-(2-oxocyclohexyl)isoindole-1,3-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCCCC1=O MJPKHSSFTWJJSX-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- CCHNWURRBFGQCD-UHFFFAOYSA-N 2-chlorocyclohexan-1-one Chemical compound ClC1CCCCC1=O CCHNWURRBFGQCD-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- NDKWDGCTUOOAPF-UHFFFAOYSA-N 2-methoxy-6-nitroaniline Chemical compound COC1=CC=CC([N+]([O-])=O)=C1N NDKWDGCTUOOAPF-UHFFFAOYSA-N 0.000 description 1
- OEJHVWAMVGGICN-UHFFFAOYSA-N 2-methylthiophene;hydrochloride Chemical compound Cl.CC1=CC=CS1 OEJHVWAMVGGICN-UHFFFAOYSA-N 0.000 description 1
- MELYYJJKRWTTNN-UHFFFAOYSA-N 2-quinazolin-2-ylguanidine Chemical compound C1=CC=CC2=NC(NC(=N)N)=NC=C21 MELYYJJKRWTTNN-UHFFFAOYSA-N 0.000 description 1
- PEMNTZYICNLRSQ-UHFFFAOYSA-N 3,4,5,6-tetrafluorobenzene-1,2-diamine Chemical compound NC1=C(N)C(F)=C(F)C(F)=C1F PEMNTZYICNLRSQ-UHFFFAOYSA-N 0.000 description 1
- QGNXDMSEEPNKCF-UHFFFAOYSA-N 3,5-difluorobenzene-1,2-diamine Chemical compound NC1=CC(F)=CC(F)=C1N QGNXDMSEEPNKCF-UHFFFAOYSA-N 0.000 description 1
- YADOEPHJIBKBCN-UHFFFAOYSA-N 3-chloro-2-nitroaniline Chemical compound NC1=CC=CC(Cl)=C1[N+]([O-])=O YADOEPHJIBKBCN-UHFFFAOYSA-N 0.000 description 1
- NVNLHLRVSHJKBN-UHFFFAOYSA-N 3-chloro-5-(trifluoromethyl)benzene-1,2-diamine Chemical compound NC1=CC(C(F)(F)F)=CC(Cl)=C1N NVNLHLRVSHJKBN-UHFFFAOYSA-N 0.000 description 1
- AXNUJYHFQHQZBE-UHFFFAOYSA-N 3-methylbenzene-1,2-diamine Chemical compound CC1=CC=CC(N)=C1N AXNUJYHFQHQZBE-UHFFFAOYSA-N 0.000 description 1
- IWFHBRFJOHTIPU-UHFFFAOYSA-N 4,5-dichlorobenzene-1,2-diamine Chemical compound NC1=CC(Cl)=C(Cl)C=C1N IWFHBRFJOHTIPU-UHFFFAOYSA-N 0.000 description 1
- PPWRHKISAQTCCG-UHFFFAOYSA-N 4,5-difluorobenzene-1,2-diamine Chemical compound NC1=CC(F)=C(F)C=C1N PPWRHKISAQTCCG-UHFFFAOYSA-N 0.000 description 1
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 description 1
- AGAHETWGCFCMDK-UHFFFAOYSA-N 4-methoxybenzene-1,2-diamine Chemical compound COC1=CC=C(N)C(N)=C1 AGAHETWGCFCMDK-UHFFFAOYSA-N 0.000 description 1
- NQUVCRCCRXRJCK-UHFFFAOYSA-N 4-methylbenzoyl chloride Chemical compound CC1=CC=C(C(Cl)=O)C=C1 NQUVCRCCRXRJCK-UHFFFAOYSA-N 0.000 description 1
- HFOFPDGUBCVRIQ-UHFFFAOYSA-N 4-methylthiophen-3-amine Chemical compound CC1=CSC=C1N HFOFPDGUBCVRIQ-UHFFFAOYSA-N 0.000 description 1
- CEEIJOOHMCRBMH-UHFFFAOYSA-N 4-methylthiophene Chemical compound CC1=[C]SC=C1 CEEIJOOHMCRBMH-UHFFFAOYSA-N 0.000 description 1
- LJFKUPGRTNTQJI-UHFFFAOYSA-N 5,6-difluoro-n-(4-methylthiophen-3-yl)-1h-benzimidazol-2-amine Chemical compound CC1=CSC=C1NC1=NC2=CC(F)=C(F)C=C2N1 LJFKUPGRTNTQJI-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- JIRMIZJTXWPODH-UHFFFAOYSA-N 6-fluoro-n-(4-methylthiophen-3-yl)-1h-benzimidazol-2-amine Chemical compound CC1=CSC=C1NC1=NC2=CC(F)=CC=C2N1 JIRMIZJTXWPODH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 239000002083 C09CA01 - Losartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 208000003417 Central Sleep Apnea Diseases 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- WGUCTLMSHWHREV-UVUXOWFKSA-N Cl.N1C(=N[C@H]2C1CCCC2)NC2=CSC=C2C Chemical compound Cl.N1C(=N[C@H]2C1CCCC2)NC2=CSC=C2C WGUCTLMSHWHREV-UVUXOWFKSA-N 0.000 description 1
- 208000003495 Coccidiosis Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- TVZCRIROJQEVOT-CABCVRRESA-N Cromakalim Chemical compound N1([C@@H]2C3=CC(=CC=C3OC([C@H]2O)(C)C)C#N)CCCC1=O TVZCRIROJQEVOT-CABCVRRESA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 102000002045 Endothelin Human genes 0.000 description 1
- 108050009340 Endothelin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 206010020591 Hypercapnia Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 206010023076 Isosporiasis Diseases 0.000 description 1
- 102000016924 KATP Channels Human genes 0.000 description 1
- 108010053914 KATP Channels Proteins 0.000 description 1
- 206010023421 Kidney fibrosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 description 1
- 101710172108 Na(+)/H(+) antiporter NhaC Proteins 0.000 description 1
- 108091006315 Na+/HCO3 − co-transport proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229940126033 PPAR agonist Drugs 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 description 1
- CYLWJCABXYDINA-UHFFFAOYSA-N Polythiazide Polymers ClC1=C(S(N)(=O)=O)C=C2S(=O)(=O)N(C)C(CSCC(F)(F)F)NC2=C1 CYLWJCABXYDINA-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 102000006633 Sodium-Bicarbonate Symporters Human genes 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- 208000034972 Sudden Infant Death Diseases 0.000 description 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 102000003938 Thromboxane Receptors Human genes 0.000 description 1
- 108090000300 Thromboxane Receptors Proteins 0.000 description 1
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 1
- JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 description 1
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- NTECHUXHORNEGZ-UHFFFAOYSA-N acetyloxymethyl 3',6'-bis(acetyloxymethoxy)-2',7'-bis[3-(acetyloxymethoxy)-3-oxopropyl]-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-carboxylate Chemical compound O1C(=O)C2=CC(C(=O)OCOC(C)=O)=CC=C2C21C1=CC(CCC(=O)OCOC(C)=O)=C(OCOC(C)=O)C=C1OC1=C2C=C(CCC(=O)OCOC(=O)C)C(OCOC(C)=O)=C1 NTECHUXHORNEGZ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- 102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N anhydrous dimethyl-acetamide Natural products CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- XAHAOEIIQYSRHJ-UHFFFAOYSA-N benzene-1,2-diamine Chemical compound NC1=CC=CC=C1N.NC1=CC=CC=C1N XAHAOEIIQYSRHJ-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- JEPPYVOSGKWVSJ-UHFFFAOYSA-N bicyclo[2.2.1]heptan-3-amine Chemical compound C1CC2C(N)CC1C2 JEPPYVOSGKWVSJ-UHFFFAOYSA-N 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 229960004064 bumetanide Drugs 0.000 description 1
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 230000001269 cardiogenic effect Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 231100000457 cardiotoxic Toxicity 0.000 description 1
- 230000001451 cardiotoxic effect Effects 0.000 description 1
- 231100000259 cardiotoxicity Toxicity 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229950004210 cromakalim Drugs 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 229960004042 diazoxide Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001037 epileptic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- DEQYTNZJHKPYEZ-UHFFFAOYSA-N ethyl acetate;heptane Chemical compound CCOC(C)=O.CCCCCCC DEQYTNZJHKPYEZ-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 229960002490 fosinopril Drugs 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- YRSVDSQRGBYVIY-GJZGRUSLSA-N gemopatrilat Chemical compound O=C1N(CC(O)=O)C(C)(C)CCC[C@@H]1NC(=O)[C@@H](S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-GJZGRUSLSA-N 0.000 description 1
- 229950006480 gemopatrilat Drugs 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000012105 intracellular pH reduction Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002171 loop diuretic Substances 0.000 description 1
- 229960004773 losartan Drugs 0.000 description 1
- KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229950004994 meglitinide Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- TWEQNZZOOFKOER-UHFFFAOYSA-N methyl 3-aminothiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1N TWEQNZZOOFKOER-UHFFFAOYSA-N 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 108010007855 mitochondrial K(ATP) channel Proteins 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RXYGHZGCKPXHJA-UHFFFAOYSA-N n-(2-bromo-4-chlorothiophen-3-yl)-5,6-difluoro-1h-benzimidazol-2-amine;hydrochloride Chemical compound Cl.N1C=2C=C(F)C(F)=CC=2N=C1NC=1C(Cl)=CSC=1Br RXYGHZGCKPXHJA-UHFFFAOYSA-N 0.000 description 1
- LKXNLDOKDPETKD-UHFFFAOYSA-N n-(2-bromo-4-chlorothiophen-3-yl)-6-fluoro-1h-benzimidazol-2-amine;hydrochloride Chemical compound Cl.N=1C2=CC(F)=CC=C2NC=1NC=1C(Cl)=CSC=1Br LKXNLDOKDPETKD-UHFFFAOYSA-N 0.000 description 1
- RBWZTXLQXSPJQL-UHFFFAOYSA-N n-(2-bromo-4-methylthiophen-3-yl)-5,6-difluoro-1h-benzimidazol-2-amine Chemical compound CC1=CSC(Br)=C1NC1=NC2=CC(F)=C(F)C=C2N1 RBWZTXLQXSPJQL-UHFFFAOYSA-N 0.000 description 1
- GUHMSCXUDCXNEP-UHFFFAOYSA-N n-(2-chloro-4-methylthiophen-3-yl)-5,6-difluoro-1h-benzimidazol-2-amine;hydrochloride Chemical compound Cl.CC1=CSC(Cl)=C1NC1=NC2=CC(F)=C(F)C=C2N1 GUHMSCXUDCXNEP-UHFFFAOYSA-N 0.000 description 1
- LINRMSLBZJQGDA-UHFFFAOYSA-N n-[(2-chloro-4-methylthiophen-3-yl)methyl]-1h-benzimidazol-2-amine Chemical compound CC1=CSC(Cl)=C1CNC1=NC2=CC=CC=C2N1 LINRMSLBZJQGDA-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 231100001143 noxa Toxicity 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 description 1
- 229950000973 omapatrilat Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 239000002307 peroxisome proliferator activated receptor agonist Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960005095 pioglitazone Drugs 0.000 description 1
- 229960001085 piretanide Drugs 0.000 description 1
- 229960005483 polythiazide Drugs 0.000 description 1
- 229920000046 polythiazide Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 208000005069 pulmonary fibrosis Diseases 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000031844 regulation of cellular pH Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 239000002461 renin inhibitor Substances 0.000 description 1
- 229940086526 renin-inhibitors Drugs 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- BEBOUWGYKDEYIL-UHFFFAOYSA-N thiophen-3-amine;hydrochloride Chemical compound Cl.NC=1C=CSC=1 BEBOUWGYKDEYIL-UHFFFAOYSA-N 0.000 description 1
- ZWZVWGITAAIFPS-UHFFFAOYSA-N thiophosgene Chemical compound ClC(Cl)=S ZWZVWGITAAIFPS-UHFFFAOYSA-N 0.000 description 1
- 150000003585 thioureas Chemical class 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 description 1
- 229960005001 ticlopidine Drugs 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 229960005371 tolbutamide Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960005461 torasemide Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229960001288 triamterene Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 108010047303 von Willebrand Factor Proteins 0.000 description 1
- 102100036537 von Willebrand factor Human genes 0.000 description 1
- 229960001134 von willebrand factor Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Description
I 1 WO 03/101984 PCT/EP03/05465 SUBSTITUTED THIOPHENES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC REAGENT, AND A MEDICAMENT CONTAINING THE SAME Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same The invention relates to compounds of the type of the substituted thiophene derivatives of the formula I. Medicaments comprising compounds of this type are of use for preventing or treating various disorders. Thus, the compounds can be used, inter alia, for the treatment of respiratory disorders and snoring, and for improving the respiratory drive, for the treatment of acute and chronic disorders, disorders triggered by ischemic and/or reperfusion events and by proliferative or fibrotic events, for the treatment or prophylaxis of disorders of the central nervous system and lipid metabolism, and diabetes, blood coagulation and infection by parasites.
The invention relates to compounds of the formula I, R3 R5 R7 S R2 N _R8 N R6 I
I
R1 R4 H in which: R1 and R2 independently of one another are H, F, CI, Br, I, CN, NO2, -(X)n-CqH2q-Z, cycloalkyl having 3, 4, 5 or 6 carbon atoms, alkenyl having 2, 3 or 4 carbon atoms, alkenylalkyl having 3 or 4 carbon atoms, ethynyl or alkylalkynyl having 3 or 4 carbon atoms; n is zero or 1; 2 X is oxygen, NH, N-CH 3 S(O)k; k is zero, 1 or 2; q is zero, 1, 2, 3, 4, 5 or 6; Z is hydrogen or CmF2m+l; m is zero, 1, 2, 3 or 4; R3 is hydrogen, methyl, F, CI, Br, I, CN, S(O)k-CH3, -NO 2
-O-CH
3 k is zero, 1 or 2; R4 is hydrogen, cycloalkyl having 3, 4, 5, or 6 carbon atoms, alkenyl having 2, 3 or 4 carbon atoms, alkenylalkyl having 3 or 4 carbon atoms, ethynyl or alkylalkynyl having 3 or 4 carbon atoms, -CrH2r Y; r is zero, 1, 2, 3 or 4; Y is hydrogen or trifluoromethyl; and R6 are hydrogen or together are a bond;.
R7 and R8 independently of one another are (C3-C5)-alkyl, (C2-C5)-alkenyl, alkynyl, (C3-C6)-cycloalkyl or (C4-C6)-cycloalkenyl or R7 and R8 together are an alkylene chain comprising 3 to 8 carbon atoms; where none, some or all of their hydrogen atoms may be replaced by fluorine atoms; or R7 and R8 together are a radical R12 R11 R9 where R5 and R6 together form a bond; and R11 independently of one another are hydrogen, fluorine, chlorine, bromine, methyl, CN, OH, -O-CH 3
NO
2
NH
2 or -CF3; R9 and R12 are hydrogen or F; or one of the substituents R9 and R12 is hydrogen; and the other is F, CI, Br, I, CN, NO 2 COOH, CO-NR13R14, SO 2 NR13R14, alkenyl having 2, 3 or 4 carbon atoms, alkenylalkyl having 3 or 4 carbon atoms, ethynyl, alkylalkynyl having 3 or 4 carbon atoms or CqH2q-Z; R13 and R14 are identical or different hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; or R13 and R14 together with the nitrogen to which they are attached form a saturated 6- or 7-membered ring; n is zero or 1; X is oxygen, NH, N-CH 3 S(O)k; k is zero, 1 or 2; q is zero, 1,2, 3, 4, 5 or 6; and Z is hydrogen or CmF2m+1; m is zero, 1, 2, 3 or 4; and their pharmaceutically acceptable salts, and their trifluoroacetic acid salts.
One embodiment relates to compounds of the formula I in which R1 and R2 independently of one another are H, F, CI, Br, I, CN, NO 2 CqH2q Z, cycloalkyl having 3, 4, 5 or 6 carbon atoms, alkenyl having 2, 3 or 4 carbon atoms, alkenylalkyl having 3 or 4 carbon atoms, ethynyl or alkylalkynyl having 3 or 4 carbon atoms; n is zero or 1; X is oxygen, NH, N-CH 3 S(O)k; k is zero, 1 or 2; q is zero, 1, 2, 3, 4, 5 or 6; Z is hydrogen or CmF2m+1; m is zero, 1, 2, 3 or 4; R3 is hydrogen, methyl, F, CI, Br, I, CN, S(O)k-CH3, -NO 2
CH
3 R4 is hydrogen, cycloalkyl having 3, 4, 5, or 6 carbon atoms, alkenyl having 2, 3 or 4 carbon atoms, alkenylalkyl having 3 or 4 carbon atoms, ethynyl or alkylalkynyl having 3 or 4 carbon atoms, -CqH2q Z; q is zero, 1, 2, 3 or 4; Z is hydrogen or trifluoromethyl; R5 and R6 are hydrogen or together are a bond; R7 and R8 independently of one another are (C3-C5)-alkyl, (C2-C5)-alkenyl, alkynyl, (C3-C6)-cycloalkyl or (C4-C6)-cycloalkenyl or R7 and R8 together are an alkylene chain comprising 3 to 8 carbon atoms; where none, some or all of their hydrogen atoms may be replaced by fluorine atoms; or R7 and R8 together are a radical R12 R11 R9 where R5 and R6 together form a bond; R9, R10 and R11 independently of one another are hydrogen, fluorine, chlorine, bromine, methyl, CN, OH, -O-CH 3
NO
2
NH
2 or -CF 3 R9 and R12 are hydrogen; or one of the substituents R9 and R12 is hydrogen; and the other is F, Cl, Br, I, CN, NO 2 COOH, CO-NR13R14, S0 2 -NR13R14, alkenyl having 2, 3 or 4 carbon atoms, alkenylalkyl having 3 or 4 carbon atoms, ethynyl, alkylalkynyl having 3 or 4 carbon atoms or CqH2q-Z; R13 and R14 are identical or different hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; n is zero or 1; X is oxygen, NH, N-CH 3 S(O)k; k is zero, 1 or 2; q is zero, 1, 2, 3, 4, 5 or 6; and Z is hydrogen or CmF2m+l; m is zero, 1, 2, 3 or 4; and their pharmaceutically acceptable salts, and their trifluoroacetic acid salts.
Preference is given to compounds of the formula I, in which: R1 and R2 independently of one another are H, F, CI, Br, CH 3
CF
3 or S02CH 3 but where at most one of the substituents R1 and R2 is hydrogen; R3 is hydrogen, F or Cl; R4 is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, or cyclopropyl; and R6 are hydrogen or together are a bond; R7 and R8 together are an alkylene chain comprising 3, 4, 5, 6, 7 or 8 carbon atoms; or R7 and R8 together are a radical R12 R11 R9 where R5 and R6 together form a bond; R10 and R11 independently of one another are hydrogen, OH, fluorine or chlorine; R9 and R12 are hydrogen; one of the substituents R9 and R12 is hydrogen; and the other is F, CI, Br, CN, COOH, CO-NR13R14, SO 2 -NR13R14 or CqH2q-Z; R13 and R14 are identical or different hydrogen or methyl; n is zero or 1; X is oxygen, NH, N-CH 3 or S(O)k; k is zero, 1 or 2; q is zero, 1, 2, 3 or 4; Z is hydrogen or CF 3 and their pharmaceutically acceptable salts, and their trifluoroacetic acid salts.
Particular preference is given to compounds of the formula I in which: R1 and R2 independently of one another are F, CI, Br, CH 3 or CF 3 R3 is hydrogen; R4 is hydrogen, methyl, ethyl; R5 and R6 are hydrogen or together are a bond; R7 and R8 together are an alkylene chain comprising 3, 4, 5, 6, 7 or 8 carbon atoms; or R7 and R8 together are a radical R12 R11 R9 where R5 and R6 together form a bond; and R11 independently of one another are hydrogen, OH or fluorine; R9 and R12 are hydrogen; or one of the substituents R9 and R12 is hydrogen; and the other is F, CI, Br or CqH2q-Z; n is zero or 1; X is oxygen, NH, N-CH 3 or S(O)k; k is zero, 1 or 2; q is zero or 1; Z is hydrogen or OF 3 and their pharmaceutically acceptable salts, and their trifluoroacetic acid salts.
Very particular preference is given to the following compounds of the formula 1, selected from the group consisting of: trans- R, R-2-chloro-3N-(3a,4,5,6,7,7a-hexahyd ro- 1 H-2-benzimidazolyl)-4-methyl-3thienylamine, trans- R, R-2-bromo-3N-(3a,4,5,6,7,7a-hexahyd ro- 1 H-2-benzimidazolyl)-4-methyl-3thienylamine, 2-chloro-3N-(2-benzimidazolyl)-4-methyl-3-thienylamine, 2-bromo-3N-(2-benzimidazolyl)-4-methyl-3-thienylamine, 2-chloro-3N-(4-methyl-2-benzimidazolyl)-4-methyl-3-thienylamine, 2-chloro-3N-(5-fluoro-2-benzimidazolyl)-4-methyl-3-thienylamine, 2-chloro-3N-(4-chloro-2-benzimidazolylamino)-4-methylthiophene, 2-bromo-3N-(4-chloro-2-benzimidazolylamino)-4-methylthiophene, 2-bromo-3N-(4-fluoro-2-benzimidazolylamino)-4-methylthiophene, 2-chloro-3N-(4-fluoro-2-benzimidazolylamino)-4-methylthiophene, 2-chloro-3N-(4-hydroxy-2-benzimidazolylamino)-4-methylthiophene, (1 H-benzimidazol-2-yl)-(2-chloro-4-methylthiophen-3-yl)-methylamine, (2-bromo-4-methylthiophen-3-yl)-(5-fluoro-1 H-benzimidazol-2-yl)-amine, 2-chloro-3N-(2-benzimidazolylamino)-4-methylthiophene, 2,4-dichloro-3N-(2-benzimidazolylamino)thiophene, 2-bromo-4-chloro-3N-(2-benzimidazolylamino)thiophene, 2,4-dichloro-3N-(4-methyl-2-benzimidazolylamino)thiophene, trans- R, R-2,4-dich loro-3N-(3a,4,5,6,7,7a-hexahyd ro- 1 H-2-benzimidazolyl)-3thienylamine, or 2,4-dichloro-3N-(4-chloro-2-benzimidazolylamino)thiophene and their pharmaceutically acceptable salts, for example the hydrochloride or the hydrobromide or the methanesulfonate of each of the compounds.
The compounds of the formula I can be present in the form of their salts. Suitable acid addition salts are salts of all pharmacologically acceptable acids, for example halides, in particular hydrochlorides, hydrobromides, lactates, sulfates, citrates, tartrates, acetates, phosphates, methylsulfonates, benzenesulfonates, p-toluenesulfonates, adipinates, fumarates, gluconates, glutamates, glycerolphosphates, maleates, benzoates, oxalates and pamoates. This group also corresponds to the physiologically acceptable anions; but also trifluoroacetates. If the compounds contain an acid group, they are capable of forming salts with bases, for example as alkali metal salts, preferably sodium or potassium salts, or as ammonium salts, for example as salts with ammonia or organic amines or amino acids. They can also be present as zwitterion.
If the compounds of the formula I contain one or more centers of asymmetry, the compounds can independently be both S- and R-configured. The compounds can be present as optical isomers, as diastereomers, as racemates or as mixtures thereof.
The compounds of the formula I can furthermore be present as tautomers or as a mixture of tautomeric structures. This refers, for example, to the following tautomers: R3 RR5 R7 R3 RR 5 R7 R3 RR5 R7 N HN 'f HN S I R8 S R8 S R8 SNN R6 N N R6 N NR6 R1 R4 H R1 R4 R1 H (if R4 H) Alkyl radicals can be straight-chain or branched. This also applies when they carry substituents or are present as substituents of other radicals, for example in fluoroalkyl radicals or alkoxy radicals. Examples of alkyl radicals are methyl, ethyl, n-propyl, isopropyl 1-methylethyl), n-butyl, isobutyl 2-methylpropyl), sec-butyl 1-methylpropyl), tert-butyl 1,1-dimethylethyl), n-pentyl, isopentyl, tert-pentyl, neopentyl or hexyl. Preferred alkyl radicals are methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, n-hexyl. In alkyl radicals, one or more, for example 1, 2, 3, 4, 5, 6, 7, 8 or 9, hydrogen atoms may be substituted by fluorine atoms. Examples of such fluoroalkyl radicals are trifluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, heptafluoroisopropyl.
Substituted alkyl radicals may be substituted in any positions.
Alkenyl radicals may be straight-chain or branched. This also applies when they are present as substituents, for example in alkenylalkylene. The alkenyl radicals can be unsaturated in different positions. Examples of alkenyl radicals are ethenyl, propenyl or butenyl.
Alkynyl radicals can be straight-chain or branched. This also applies when they are present as substituents, for example in alkynylalkylene. The alkynyl radicals can be unsaturated in different positions. Examples of alkynyl radicals are ethynyl, propynyl or butynyl.
Examples of cycloalkyl radicals are cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
Substituted cycloalkyl radicals can be substitued in any positions. The cycloalkyl radicals may also be present branched as alkylcycloalkyl or cycloalkylalkyl.
Also described are methods for preparing compounds according to the invention.
Thus, the substances described by formula I can be prepared in a manner known to the person skilled in the art from the isothiocyanate II parent compounds and the appropriate diamines Ill.
R3 R2 R3 R2 R5 R7 S N=C=S H2NR8 R1 H 2 N R6 The thiourea derivative which is formed as an intermediate is cyclized using methyliodide (Synthesis, 1974, 41 42) or carbodiimide (Synthesis, 1977, 864 865) or using p-toluenesulfonyl chloride to give the corresponding compound of the formula I. If the isothiocyanates II employed here are not commercially available, they can be prepared in a manner known from the literature from the corresponding aminothiophene derivatives, using methods known to the person skilled in the art, for example by treatment with thiophosgene Med. Chem., 1975, 18, 90-99) or thiocarbonyl diimidazole (Justus Liebigs Ann. Chem., 1962, 657, 104).
In addition to the isothiocyanates II described above, it is also possible to successfully react the isocyanates IV R3 2
N=C=O
R1
IV
with amines of the type of formula III to give the compounds of the formula I. Here, the urea derivative which is formed as an intermediate is cyclized using phosphorus oxychloride to give the corresponding compounds of the formula I.
In the present invention, it was surprisingly possible to demonstrate that the compounds described are potent inhibitors of the sodium/proton exchanger (NHE), in particular the sodium/proton exchanger of subtype 3 (NHE3).
The NHE3 inhibitors known to date are derived from compounds of the acylguanidine type (EP825178), of the norbornylamine type (DE199 60 204), of the 2-guanidinoquinazoline type (WO 0179186) or of the benzamidine type (WO0121582, WO0172742). Squalamine, which has also been described as NHE3 inhibitor Donowitz et al. Am. J. Physiol. 276 (Cell Physiol. 45): C136 C144), is, according to current understanding, not, unlike the compounds of the formula I, effective immediately, but rather via an indirect mechanism and thus reaches its maximum potency only after one hour. Such NHE3 inhibitors which act by a different mechanism are therefore suitable for use as combination partners for the present compounds according to the invention.
Clonidine, which is similar to the compounds described here, is known as a weak NHE inhibitor. However, its action on the NHE3 of the rat is, with a half-maximal inhibitory concentration (IC 50 of 620 pM, extremely moderate. In contrast, it shows a certain selectivity for the NHE2 Orlowski et al. J. Biol. Chem. 268, 25536). It would therefore be more accurate to refer to clonidine as an NHE2 inhibitor. In addition to the weak NHE action, clonidine has a high affinity for the adrenergic alpha2 receptor and the imidazoline 11 receptor, mediating a strong hypotensive action (Ernsberger et al., Eur. J. Pharmacol. 134, 1, 1987).
Clonidine-like compounds having a thiophene ring instead of the phenyl ring are known from DE1941761. These known compounds differ from the structures of the formula I described herein in that they have considerably smaller radicals R7 and R8 and in particular by the fact that R7 and R8 are not capable of forming a joint ring.
By these differences in the substituents R7 and R8, it is possible to eliminate the undesirable clonidine-like cardiovascular effects described above, which are mediated by the alpha-adrenoceptor action. At the same time, owing to these differences in the substituents, the NHE-inhibiting properties of the compounds described herein are enhanced to the micromolar and submicromolar range, whereas the compounds known from DE1941761 show only extremely weakly pronounced NHE-inhibiting effects, if any. Thus the main representative compound from DE1941761, the hypotensive agent thiamenidine selected as development product, has, in each case at 300 pM, no inhibiting effects on the NHE-subtypes NHE1, NHE2, NHE3 and which were tested.
Compounds of the formula I are distinguished in that they inhibit the cellular sodium/proton exchanger, and in particular by their NHE3-inhibitory action.
NHE3 is found in the body of various species, preferably in the gall bladder, the intestine and the kidney (Larry Fliegel et al., Biochem. Cell. Biol. 76: 735 741, 1998), but can also be detected in the brain Ma et al., Neuroscience 79: 591 603).
Owing to the NHE-inhibitory properties, the compounds of the formula I are suitable for the prevention and treatment of diseases caused by an activation of NHE or by an activated NHE, and of diseases which are sequelae of damage caused by NHE.
Since NHE inhibitors act predominantly via influencing cellular pH regulation, they can be combined in a favorable manner with other compounds which also regulate the intracellular pH, suitable combination partners being inhibitors of the enzyme group of the carbonate dehydratases, inhibitors of the bicarbonate-ion-transporting systems, such as the sodium bicarbonate cotransporter (NBC) or the sodium-dependent chloride/bicarbonate exchanger (NCBE), and also NHE inhibitors having inhibitory action on other NHE subtypes, since they can modulate or enhance the pharmacologically relevant pH-regulating effects of the NHE inhibitors described herein.
The use of the compounds according to the invention relates to the prevention and treatment of acute and chronic diseases in veterinary and human medicine.
The pharmacological action of the compounds of the formula I is characterized in that they induce an improvement in the respiratory drive. They can therefore be used in the treatment of disturbed respiratory conditions which may, for example, occur in the following clinical conditions and diseases: disturbed central respiratory drive (e.g.
central sleep apnea, sudden infant death, postoperative hypoxia), muscular-related respiratory disorders, respiratory disorders after long-term ventilation, respiratory disorders during adaptation in a high mountain area, obstructive and mixed forms of sleep apnea, acute and chronic lung diseases with hypoxia and hypercapnia.
The compounds additionally increase the muscle tone of the upper airways, so that snoring is suppressed. As a result, the compounds mentioned are advantageously used for preparing a medicament for the prevention and treatment of sleep apnea and muscular-related respiratory disturbances and for preparing a medicament for the prevention and treatment of snoring.
A combination of an NHE inhibitor of the formula I with a carboanhydrase inhibitor (e.g.
acetazolamide) may prove to be advantageous, the latter producing metabolic acidosis and thereby already increasing respiratory activity, as a result of which an increased action and decreased use of active compound may be achieved.
Owing to their NHE3-inhibitory action, the compounds according to the invention spare cellular energy resources which, during toxic and pathogenic events, are rapidly depleted, thus resulting in cell damage or cell death. Here, the high-energy ATPconsuming resorption of sodium in the proximal tubulus is, under the influence of the compounds of the formula I, temporarily switched off, and the cell is thus able to survive an acute pathogenic, ischemic or toxic situation. The compounds are therefore suitable by way of example for use as drugs for treating ischemic noxa, for example acute kidney failure.
Furthermore, the compounds are also suitable for treating all chronic renal disorders and forms of nephritis which, as a consequence of increased elimination of protein, result in chronic kidney failure. Accordingly, the compounds of the formula I are suitable for preparing a medicament for the treatment of diabetic late damage, diabetic nephropathy and chronic renal disorders, in particular all inflammations of the kidney (nephritides) associated with increased elimination of protein/albumin.
It has been shown that the compounds used according to the invention have mild laxative action and, accordingly, can also be used advantageously as laxatives or for the prophylaxis of intestinal obstruction.
Furthermore, the compounds according to the invention can be used advantageously for the prevention and therapy of acute and chronic disorders of the intestinal tract triggered, for example, by ischemic states in the intestinal region and/or by subsequent reperfusion or by states and events of inflammation. Such complications can occur, for example, by lack of intestinal peristalsis, as is frequently observed, for example, after surgical interventions, in the case of bowel obstruction or in cases of strongly reduced intestinal motility.
Using the compounds according to the invention, it is possible to prevent gallstone formation.
The NHE inhibitors according to the invention are generally suitable for treating diseases caused by ischemia and by reperfusion.
As a result of their pharmacological properties, the compounds according to the invention are suitable for use as antiarrhythmics.
Owing to their cardioprotective component, the NHE inhibitors of the formula I are highly suitable for infarct prophylaxis and infarct treatment and for treatment of angina pectoris, and they also inhibit, or strongly reduce, in a preventative manner, the pathophysiological processes which contribute to ischemically induced damage, in particular those which trigger ischemically induced cardiac arrhythmias. Owing to their protective action against pathological hypoxic and ischemic situations, the compounds of the formula I used according to the invention can, as inhibitors of the cellular Na+/H exchange mechanism, be used as medicaments for treating all acute or chronic damage caused by ischemia, or diseases induced primarily or secondarily by this damage.
This relates to their use as medicaments for surgical interventions. Thus, the compounds according to the invention can be used for organ transplantations, where the compounds can be used both for protecting the organs in the donor before and during removal, for protecting organs that have been removed, for example during treatment with or storage in physiological bath fluids, and also during transfer into the recipient organism pretreated with compounds of the formula I.
The compounds are also useful medicaments with protective action during angioplastic surgical interventions, for example on the heart, but also in peripheral organs and vessels.
Since NHE inhibitors protect human tissue and organs not only effectively against damage caused by ischemia and reperfusion but also against the cytotoxic action of medicaments used in particular in cancer therapy and the therapy of autoimmune diseases, the combined administration with compounds of the formula I is suitable for suppressing or reducing the cytotoxic effects of a therapy. By reducing the cytotoxic effects, in particular cardiotoxicity, by comedication with NHE inhibitors it is furthermore possible to increase the dose of the cytotoxic therapeutics and/or to prolong medication with such medicaments. The therapeutic benefit of such a cytotoxic therapy can be enhanced considerably by combination with NHE inhibitors.
The compounds of the formula I are suitable in particular for improving the therapy with medicaments having an undesirable cardiotoxic component.
Owing to their protective action against ischemically induced damage, the compounds according to the invention are also suitable for use as medicaments for treating ischemias of the nervous system, in particular the central nervous system, where they can be used, for example, for treating stroke or cerebral edema.
The compounds of formula I are also suitable for the therapy and prophylaxis of diseases and disorders induced by overexcitability of the central nervous system, in particular for the treatment of epileptic disorders, centrally induced clonic and tonic spasms, states of psychological depression, anxiety disorders and psychoses. Here, the NHE inhibitors according to the invention can be used on their own or in combination with other substances having antiepileptic action or with antipsychotic active compounds, or carbonate dehydratase inhibitors, for example acetazolamide, and also with other inhibitors of NHE or of the sodium-dependent chloride/bicarbonate exchanger (NCBE).
In addition, the compounds of the formula I according to the invention are also suitable for treating types of shock, such as, for example, of allergic, cardiogenic, hypovolemic and bacterial shock.
The compounds of the formula I can also be used for the prevention and treatment of thrombotic disorders since, as NHE inhibitors, they are also capable of inhibiting platelet aggregation themselves. In addition, they can prevent or inhibit excessive release of mediators of inflammation and coagulation, in particular of the von Willebrand factor and thrombogenic selecting proteins which takes place following ischemia and reperfusion. It is thus possible to reduce and eliminate the pathogenic effect of significant thrombogenic factors. Accordingly, the NHE inhibitors of the present invention can be combined with other compounds having anticoagulative and/or thrombolytic action, such as, for example, recombinant or natural tissue plasminogen activator, streptokinase, urokinase, acetylsalicylic acid, thrombin antagonists, factor Xa antagonists, medicaments with fibrinolytic action, thromboxane receptor antagonists, phosphodiesterase inhibitors, factor Vila antagonists, clopidogrel, ticlopidine, etc. Combined use of the present NHE inhibitors with NCBE inhibitors and/or with inhibitors of carbonate dehydratase, such as, for example, with acetazolamide, is particularly beneficial.
Furthermore, the compounds of the formula I according to the invention have strong inhibiting action on cell proliferation, for example on fibroblast cell proliferation and proliferation of smooth vascular muscle cells. The compounds of the formula I are therefore useful therapeutics for diseases in which cell proliferation is a primary or secondary cause and can therefore be used as antiatherosclerotics, as agents against chronic kidney failure and against neoplastic diseases. Thus, they can be used for treating organ hypertrophy and hyperplasia, for example of the heart and the prostate.
Compounds of the formula I are therefore suitable for the prevention and treatment of cardiac insufficiency (congestive heart failure CHF) and for the treatment and prevention of prostate hyperplasia and prostate hypertrophy.
The compounds of the formula I furthermore delay or prevent fibrotic disorders. Thus, they are excellent agents for treating fibroses of the heart, and also pulmonary fibrosis, liver fibrosis, kidney fibrosis and other fibrotic disorders.
Since there is significant elevation of NHE in essential hypertensives, the compounds of the formula I are suitable for the prevention and treatment of high blood pressure and of cardiovascular disorders.
Here, they can be used for the treatment of high blood pressure and of cardiovascular disorders on their own or with a suitable combination and formulation cocomponent.
Thus, it is possible, for example, to combine one or more diuretics having thiazide-like action, loop diuretics, aldosterone and pseudoaldosterone antagonists, such as hydrochlorothiazide, indapamide, polythiazide, furosemide, piretanide, torasemide, bumetanide, amiloride, triamterene, spironolactone or eplerone, with compounds of the formula I. Furthermore, the NHE inhibitors of the present invention can be used in combination with calcium antagonists such as verapamil, diltiazem, amlodipine or nifedipine, and also with ACE inhibitors, such as, for example, ramipril, enalapril, lisinopril, fosinopril or captopril. Further favorable combination partners include betablockers such as metoprolol, albuterol etc., antagonists of the angiotensin receptor and its receptor subtypes, such as losartan, irbesartan, valsartan, omapatrilat, gemopatrilat, endothelin antagonists, renin inhibitors, adenosine receptor agonists, inhibitors and activators of calcium channels, such as glibenclamide, glimepiride, diazoxide, cromakalim, minoxidil and its derivatives, activators of the mitochondrial ATP-sensitive potassium channel (mitoK(ATP) channel), inhibitors of other potassium channels, such as inhibitors of Kv1.5 etc.
Owing to their antiphlogistic action, the NHE inhibitors can be used as antiinflammatory agents. Mechanistically interesting is the inhibition of the release of mediators of inflammation. Thus, the compounds can be used alone or in combination with an antiphlogistic agent for the prevention or treatment of chronic and acute inflammatory disorders. The combination partners used are advantageously steroidal and nonsteroidal antiinflammatory agents.
Moreover, it has been found that compounds of the formula I exert a beneficial influence on serum lipoproteins. They can therefore be used for the prophylaxis and regression of atherosclerotic changes by excluding a causal risk factor. This includes not only primary hyperlipidemias but also certain secondary hyperlipidemias as are encountered, for example, in diabetes. Additionally, the compounds of the formula I reduce infarcts induced by metabolic anomalies considerably and, in particular, lead to a significant reduction in the size and severity of the infarct induced.
Accordingly, the compounds mentioned are used advantageously for preparing a medicament for the treatment of hypercholesterolemia, for preparing a medicament for the prevention of atherogenesis, for preparing a medicament for the prevention and treatment of atherosclerosis, for preparing a medicament for the prevention and treatment of diseases induced by elevated cholesterol levels, for preparing a medicament for the prevention and treatment of diseases induced by endothelial dysfunction, for preparing a medicament for the prevention and treatment of hypertension induced by atherosclerosis, for preparing a medicament for the prevention and treatment of thromboses induced by atherosclerosis, for preparing a medicament for the prevention and treatment of ischemic damage and post-ischemic reperfusion damage induced by hypercholesterolemia and endothelial dysfunction, for preparing a medicament for the prevention and treatment of cardiac hypertrophies and cardiomyopathies and congestive heart failure (CHF), for preparing a medicament for the prevention and treatment of coronary vascospasms and myocardial infarcts induced by hypercholesterolemia and endothelial dysfunction, for preparing a medicament for the treatment of the conditions mentioned in combination with hypotensive substances, preferably with angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists. A combination of an NHE inhibitor of the formula I with an active compound that lowers the lipid concentration in the blood, preferably an HMG-CoA reductase inhibitor (for example lovastatin or pravastatin), the latter having hypolipidemic action, thereby enhancing the hypolipidemic properties of the NHE inhibitor of the formula I, has been found to be a favorable combination with increased action and reduced use of active compound.
Thus, compounds of the formula I bring about effective protection against endothelial damage of various origins. Owing to this protection of the vessels against the syndrome of endothelial dysfunction, compounds of the formula I are useful medicaments for the prevention and treatment of coronary vascospasms, peripheral vascular diseases, in particular intermittent claudication, of atherogenesis and atherosclerosis, of left-ventricular hypertrophy and of dilated cardiomyopathy, and of thrombotic disorders.
Moreover, NHE inhibitors of the formula I are suitable for treating non-insulindependent diabetes (NIDDM) where, for example, insulin resistance is suppressed.
Here, to enhance antidiabetic efficacy and quality of action of the compounds according to the invention, it may be favorable to combine these compounds with a biguanide such as metformin, with an antidiabetic sulfonylurea, such as glyburide, glimepiride, tolbutamide, etc., a glucosidase inhibitor, a PPAR agonist, such as rosiglitazone, pioglitazone, etc., with an insulin product in a different administration form, with a DB4 inhibitor, with an insulin sensitizer or with meglitinide.
In addition to the acute antidiabetic effects, the compounds of the formula I counteract the development of late complications of diabetes, and they can therefore be used as medicaments for the prevention and treatment of diabetic late damage, such as diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, diabetic cardiomyopathy and other disorders which occur as a result of diabetes. In this connection, they can be combined advantageously with the antidiabetic medicaments described above under the NIDDM treatment. A combination with a favorable administration form of insulin may be of particular importance.
In addition to the protective effects against acute ischemic events and subsequent likewise acute reperfusion events, the NHE inhibitors of the formula I according to the invention also have direct therapeutically useful action against disorders and impairments of the entire mammalian organism which are associated with manifestations of the chronically progressing aging process and are also independent of acute states of hypoperfusion, and may also occur under normal, non-ischemic conditions. These pathological age-related manifestations, such as disease, illness and death, induced over the long time of aging, which are now accessible to treatment with NHE inhibitors, are disorders and disturbances caused to a substantial extent by age-related changes in vital organs and their function which become more and more important in the aging organism.
Disorders associated with age-related dysfunction and age-related symptoms of wear of organs are, for example, inadequate responsiveness and reactivity of the blood vessels to contraction and relaxation reactions. This age-related decline in vascular reactivity to constricting and relaxing stimuli, which are an essential process of the cardiovascular system and thus of life and health, can be significantly diminished or abolished by NHE inhibitors. An important function and a measure of the maintenance of vascular reactivity is the blocking or slowing of the age-related progression of endothelial dysfunction, which can be abolished highly significantly by NHE inhibitors.
The compounds of the formula I are thus outstandingly suitable for the treatment and prevention of the age-related progression of endothelial dysfunction, especially of intermittent claudication. Moreover, the compounds of the formula I are thus outstandingly suitable for the treatment and prevention of cardiac insufficiency, of congestive heart failure (CHF), and for the treatment and in particular for the prevention of age-related types of cancer.
Consideration may likewise be given to combination with hypotensive medicaments, such as with ACE inhibitors, angiotensin receptor antagonists, diuretics, Ca 2 antagonists, etc., or with metabolism-normalizing medicaments, such as cholesterollowering agents. The compounds of the formula I are thus suitable for the prevention of age-related tissue changes and for prolonging life while maintaining a high quality of life.
The compounds of the invention are effective inhibitors of the cellular sodium/proton antiporter (Na/H exchanger) which, in numerous disorders (essential hypertension, atherosclerosis, diabetes, etc.), is also elevated in cells which are easily amenable to measurements, such as, for example, in erythrocytes, platelets or leukocytes. The compounds used according to the invention are therefore suitable as excellent and simple scientific tools, for example in their use as diagnostic aids for the determination and differentiation of particular types of hypertension, but also of atherosclerosis, of diabetes and of late complications of diabetes, of proliferative disorders, etc.
NHE3 inhibitors are furthermore suitable for treating disorders (human and veterinary) caused by bacteria and by protozoa. In the case of disorders caused by protozoa, particular mention may be made of malaria diseases of man and of coccidiosis in poultry.
Moreover, the compounds are suitable as agents for controlling sucking parasites in human and veterinary medicine and in crop protection. Here, the use as an agent against blood-sucking parasites in human and veterinary medicine is preferred.
In addition to their value as potent NHE-inhibitors, their pharmacological properties and the absence of undesired biological actions, the compounds of the formula I are also distinguished by favorable pharmacokinetic properties which make their use as medicament seem particularly advantageous.
The invention thus relates to medicaments for human, veterinary or phytoprotective use which comprise an effective amount of a compound of the formula I and/or a pharmaceutically acceptable salt thereof alone or in combination with other pharmacologically active compounds or medicaments.
Medicaments comprising a compound I can be administered, for example, orally, parenterally, intramuscularly, intravenously, rectally, nasally, by inhalation, subcutaneously or by a suitable transcutaneous administration form, with the preferred administration being dependent on the particular appearance of the disorder. Here, the compounds I can be used alone or together with pharmaceutical excipients, both in veterinary medicine and in human medicine and in crop protection.
Excipients suitable for the desired pharmaceutical formulation are familiar to the skilled worker on the basis of his expert knowledge. Besides solvents, gel formers, suppository bases, tablet excipients and other active ingredient carriers, it is possible to use, for example, antioxidants, dispersants, emulsifiers, antifoams, masking flavors, preservatives, solubilizers or colorants.
For a form for oral use, the active compounds are mixed with the additives suitable for this purpose, such as carriers, stabilizers or inert diluents, and converted by conventional methods into suitable dosage forms such as tablets, coated tablets, twopiece capsules, aqueous, alcoholic or oily solutions. Examples of inert carriers which can be used are gum arabic, magnesia, magnesium carbonate, potassium phosphate, lactose, glucose or starch, especially corn starch. Preparation can moreover take place both as dry and as wet granules. Examples of suitable oily carriers or solvents are vegetable or animal oils such as sunflower oil or fish liver oil.
For subcutaneous, percutaneous or intravenous administration, the active compounds used are converted into a solution, suspension or emulsion, if desired with the substances customary for this purpose, such as solubilizers, emulsifiers or other excipients. Examples of suitable solvents are: water, physiological saline or alcohols, for example ethanol, propanol, glycerol, and also sugar solutions, such as glucose or mannitol solutions, or else a mixture of the various solvents mentioned.
Suitable as pharmaceutical formulation for administration in the form of aerosols or sprays are, for example, solutions, suspensions or emulsions of the active compound of the formula I in a pharmaceutically acceptable solvent, such as, in particular, ethanol or water, or a mixture of such solvents.
The formulation may, if required, also comprise other pharmaceutical excipients such as surfactants, emulsifiers and stabilizers, and a propellant gas. Such a preparation normally contains the active compound in a concentration of about 0.1 to 10, in particular of about 0.3 to 3% by weight.
The dosage of the active compound of the formula I to be administered and the frequency of administration depend on the potency and duration of action of the compounds used; also on the nature and severity of the disease to be treated, and on the sex, age, weight and individual response of the mammal to be treated.
On average, the daily dose of the compound of the formula I for a patient weighing about 75 kg is at least 0.001 mg/kg, preferably 0.1 mg/kg, up to a maximum of mg/kg, preferably 1 mg/kg, of body weight. In acute situations, for example immediately after suffering high-altitude breathing disorders, it may even become necessary for the dosages to be higher. Especially on i.v. use, for example for an infarct patient in an intensive care unit, up to 200 mg/kg per day may be necessary.
The daily dose can be divided into one or more, for example up to 4, individual doses.
Description of the experiments and examples: If the compounds are enantiomerically pure, the configuration and/or the sign of the optical rotation is given. If these data are missing, the compounds are racemates or not optically active.
The retention times (Rt) given below refer to LCMS measurements with the following parameters: Analytical methods:
A
stationary phase: mobile phase:
B
stationary phase: mobile phase: Merck Purospher 3/ 2 x 55 mm 95% H20 HCOOH) 95% acetonitrile (0.1% HCOOH); 5 min 95% acetonitrile HCOOH); 2 min 95% H20 HCOOH); 1 min; 0.45 ml/min.
YMC J'sphere H80 ~4p 2.1 x 33 mm 95% H20 HCOOH) 95% acetonitrile (0.08% HCOOH); 2.5 min 95% acetonitrile (0.08% HCOOH); min 95% H 2 0 HCOOH); 0.5 min; 1.3 ml/min.
YMC J'sphere H80, 4p, 2.1 x 20 mm 90% H20 (0.05% TFA) 95% acetonitrile; 1.9 min; acetonitrile 0.5 min; 1 ml/min.
Merck Purospher 3p 2 x 55 mm 95% H 2 0 HCOOH)-* 95% acetonitrile (0.1% HCOOH); 3.4 min 95% acetonitrile HCOOH); 1 min 95% H 2 0 HCOOH); 0.2 min; 0.75 ml/min.
C
stationary phase: mobile phase: stationary phase: mobile phase: stationary phase: Merck Purospher 3p 2 x 55 mm mobile phase: 95% H20 (0.05% CF3COOH)-> 95% acetonitrile (0.05% CF3COOH); 3.4 min 95% acetonitrile (0.05% CF3COOH); 1 min; 0.75 ml/min.
YMC J'sphere H80, 4p, 2.1 x 20 mm 96% H20 (0.05% CF3COOH)-> 95% acetonitrile; 2 min; acetonitrile 0.4 min; 1 ml/min.
stationary phase: mobile phase: Preparative HPLC was carried out under the following conditions: stationary phase: Merck Purospher RP18 (10/M) 250 x 25 mm mobile phase: 90% H 2 0 (0.05% TFA)- 90% acetonitrile; 40 min; ml/min Example 1: 3N-(5-Fluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HCI a) 4-Methyl-3-thienyl isothiocyanate is obtained by reacting equimolar amounts of 3-amino-4-methylthiophene and N,N'-thiocarbonyldiimidazole in anhydrous tetrahydrofuran (THF) by stirring the reaction mixture at room temperature for 5 hours and then allowing the mixture to stand at room temperature overnight. 4-Methyl-3-thienyl isothiocyanate is isolated by distillative removal of the solvent under reduced pressure using a rotary evaporator, dissolving the residue in ethyl acetate and washing the organic phase repeatedly with water. The organic phase is dried over sodium sulfate and the organic solvent is then distilled off under reduced pressure using a rotary evaporator, giving 4-methyl-3-thienyl isothiocyanate as a brown oily residue. 4-Methyl-3-thienyl isothiocyanate can be used without further purification.
b) N-(2-Amino-5-fluorophenyl)-N'-(4-methyl-3-thienyl)thiourea 0.02 mol of 4-fluoro-1,2-diaminobenzene is added to a solution of 0.02 mol of 4-methyl-3-thienyl isothiocyanate in 60 ml of anhydrous THF. The reaction mixture is stirred at room temperature for 2 hours and then allowed to stand overnight, and the solvent is then distilled off under reduced pressure using a rotary evaporator and the oily residue is purified on a silica gel column using a mixture of identical proportions of toluene and ethyl acetate.
Brown crystalline solid. M.p. 180°C.
c) 3N-(5-Fluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride A molar excess (about 1.5 to 4 mol) of methyl iodide is added to 1.5 g (0.0053 mol) of N-(2-amino-5-fluorophenyl)-N'-(4-methyl-3-thienyl)thiourea in 50 ml of anhydrous ethanol, and the mixture is boiled at reflux for 5 hours. The mixture is allowed to stand at room temperature overnight and the ethanol is then distilled off under reduced pressure using a rotary evaporator, water is added to the residue and the pH is adjusted to 8-9 using saturated aqueous sodium bicarbonate solution. The mixture is extracted repeatedly with ethyl acetate, the organic phase is washed with water and dried over sodium sulfate, the solvent is distilled off under reduced pressure using a rotary evaporator and the residue is purified by silica gel column chromatography using a solvent mixture of identical proportions of ethyl acetate and toluene (hereinbelow referred to as "mixture as mobile phase. The oily product obtained after distillative removal of the organic solvent is dissolved in ethyl acetate and made highly acidic using a saturated solution of hydrogen chloride in dry diethyl ether, and the precipitate that crystallizes out is, after relatively long standing, filtered off. Crystalline solid, m.p.
192 Example 2: 2-Chloro-3N-(5-fluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and 2,5-dichloro-3N-(5-fluoro-2-benzimidazolyl)-4-methyl- 3-thienylamine hydrochloride x HCI x HCI F N
F
H C1 Cl S CI S A solution of 0.24 g (0.0018 mol) of N-chlorosuccinimide in 15 ml of glacial acetic acid is added dropwise to a solution of 0.5 g (0.0018 mol) of 3N-(5-fluoro-2-benzimidazolyl)- 4-methyl-3-thienylamine hydrochloride in 25 ml of glacial acetic acid, the reaction mixture is stirred at room temperature for about 2 to 3 hours and the solvent is distilled off under reduced pressure using a rotary evaporator. Water is added to the residue and the mixture is then made alkaline using 2N NaOH and extracted with ethyl acetate, the organic phase is washed with water and dried over sodium sulfate and the solvent is distilled off under reduced pressure using a rotary evaporator. The resulting oily residue is, by medium pressure column chromatography, using a solvent mixture of parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid (hereinbelow referred to as "mixture 17") as mobile phase, separated and treatment with a solution of hydrogen chloride gas gives:.
2-chloro-3N-(5-fluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride from fraction 1 and 2: colorless to slightly yellowish crystalline product, m.p. 200-2020C, 2,5-dichloro-3N-(5-fluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride from fraction 3: colorless to slightly yellowish crystalline product, m.p. 286-2880C.
Example 3: 3N-(5,6-Dichloro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HCI a) N-(2-Amino-4,5-dichlorophenyl)-N'-(4-methyl-3-thienyl)thiourea is obtained analogously to the reaction described in example 1 b) from 4-methyl- 3-thienyl isothiocyanate and 4,5-dichloro- 1,2-diaminobenzene. Crystalline solid, m.p. 310-3200C.
b) 3N-(5,6-Dichloro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride is obtained analogously to the procedure described in example 1 c) from N-(2-amino- 4,5-dichlorophenyl)-N'-(4-methyl-3-thienyl)thiourea and methyl iodide.
Crystalline solid, m.p. 290-2940C.
Example 4: 3N-(2-Benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HCI a) N-(2-Aminophenyl)-N'-(4-methyl-3-thienyl)thiourea is obtained analogously to the reaction described in example 1 b) from 4-methyl- 3-thienyl isothiocyanate and 1 ,2-diaminobenzene. Crystalline solid having a 1 st m.p. of 177-1 8200, followed by another crystallization and 2nd m.p. 285-2900C.
b) 3N-(2-Benzimidazolyl)-4-methyl-3-thienylamine hydrochloride is obtained analogously to the procedure described in example 1 c) from N-(2-aminophenyl)-N'-(4-methyl-3-thienyl)thiourea and methyl iodide.
Crystalline solid following recrystallization from ethyl acetate/ethanol, m.p. 194-200 0
C.
Example 5: 3N-(-4-Fluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HCI a) 3-Fluoro-1 ,2-diaminobenzene is obtained as an oily amorphous product by hydrogenation of 3-f luoro-2-nitrophenyl hydrazine (prepared by reaction of 2,6-difluoronitrobenzene with hydrazine hydrate) using hydrogen and 10% palladium on carbon catalyst in methanol at room temperature and atmospheric pressure.
b) N-(2-Amino-3-fluorophenyl)-N'-(4-methyl-3-thienyl)thiourea is obtained analogously to the reaction described in example 1 b) from 4-methyl- 3-thienyl isothiocyanate and 3-fluoro-1,2-diaminobenzene. Crystalline solid, point of decomposition 2400C.
c) 3N-(-4-Fluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride is obtained analogously to the procedure described in example 1 c) from N-(2-amino- 3-fluorophenyl)-N'-(4-methyl-3-thienyl)thiourea and methyl iodide. Amorphous precipitate which crystallizes under acetone. Crystalline solid, m.p. 220-230 0
C.
Example 6: 3N-(4,6-Difluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride F x HCI
NN
F
S
a) N-(2-Amino-3,5-difluorophenyl)-N'-(4-methyl-3-thienyl)thiourea is obtained analogously to the reaction described in example 1 b) from 4-methyl- 3-thienyl isothiocyanate and 3,5-difluoro-1,2-diaminobenzene. Crystalline solid, 1st melting point: 178-1820C, another crystallization with 2nd 299-3010C.
b) 3N-(4,6-Difluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride is obtained analogously to the procedure described in example 1 c) from N-(2-amino- 3,5-difluorophenyl)-N'-(4-methyl-3-thienyl)thiourea and methyl iodide. Amorphous precipitate which crystallizes under ethyl acetate. Crystalline solid, m.p. 232-234oC.
Example 7: 3N-(4,5,6,7-Tetrafluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HOI a) N-(2-Amino-3,4,5,6-tetrafluorophenyl)-N'-(4-methyl-3-thienyl)thiourea is obtained analogously to the reaction described in example 1 b) from 4-methyl- 3-thienyl isothiocyanate and 3,4,5,6-tetrafluoro-1 ,2-diaminobenzene. Crystalline solid, 286-2900C.
b) 3N-(3,4,5 ,6-Tetrafluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride is obtained analogously to the procedure described in example 1 c) from N-(2-amino- 3,4,5,6-tetrafluorophenyl)-N'-(4-methyl-3-thienyl)thiou rea and methyl iodide.
Amorphous precipitate which crystallizes under ethyl acetate. Crystalline solid, m.p. 225-2280C.
Example 8: 3N-(4-Methyl-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HCI
S
a) N-(2-Amino-3-methylphenyl)-N'-(4-methyl-3-thienyl)thiou rea is obtained analogously to the reaction described in example 1 b) from 4-methyl- 3-thienyl isothiocyanate and 3-methyl-i ,2-diaminobenzene. Crystalline solid, m.p.
184-1860C, b) 3N-(4-Methyl-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride is obtained analogously to the procedure described in example 1 c) from N-(2-amino- 3-methylphenyl)-N'-(4-methyl-3-thienyl)thiourea and methyl iodide. Amorphous precipitate which crystallizes under acetone. Crystalline solid, point of decomposition: 3200C.
Example 9: trans-3N-(3a,4,5,6,7,7a-Hexahydro-1 H-2-benzimidazolyl)-4-methyl- 3-thienylamine hydrochloride (racemate) x HCI H
S
a) trans-N-(2-Aminocyclohexyl)-N'-(4-methyl-3-thienyl)thiourea (racemate) is obtained analogously to the reaction described in example 1 b) from 4-methyl- 3-thienyl isothiocyanate and racemic trans-1,2-diaminocyclohexane. Crystalline solid, m.p. 205-2100C, b) trans-3N-(3a,4,5,6,7,7a-Hexahydro-1 H-2-benzimidazolyl)-4-methyl- 3-thienylamine hydrochloride (racemate) 0.6 g of racemic trans-N-(2-aminocyclohexyl)-N'-(4-methyl-3-thienyl)thiourea is suspended in 60 ml of toluene and dissolved by heating at 900C. The mixture is allowed to cool to 700C, a solution of 0.376 g of dicyclohexylcarbodiimide in 5 ml of anhydrous toluene is added dropwise and the mixture is stirred for a total of about hours at 700C and for 2-3 days at room temperature. The crystalline solid is filtered off, the solvent is removed under reduced pressure using a rotary evaporator and the resulting oily residue is dissolved in a little ethyl acetate. Following addition of an anhydrous solution of hydrogen chloride in diethyl ether, a viscous precipitate is formed which, after addition of a little ethanol, crystallizes. Crystalline solid, 261-2640C.
Example 10: trans-R,R-3N-(3a,4,5,6,7,7a-Hexahydro-1 H-2-benzimidazolyl)- 4-methyl-3-thienylamine hydrochloride x HCI a) trans-R, R-N-(2-Aminocyclohexyl)-N'-(4-methyl-3-thienyl)thiourea is obtained analogously to the reaction described in example 1 b) from 4-methyl- 3-thienyl isothiocyanate and trans-R,R-1,2-diaminocyclohexane by separation by silica gel column chromatography, eluting with a solvent mixture consisting of 10 parts of ethyl acetate, 5 parts of n-heptane, 5 parts of methylene chloride, 5 parts of methanol and 1 part of 26% strength aqueous ammonia (hereinbelow referred to as "mixture as an amorphous oily product in addition to a crystalline product having a higher molecular weight of m.p. 94-100°C.
The amorphous product is processed further without further purification.
trans-R, R-N-(3a,4,5,6,7,7a-Hexahydro-1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride is obtained analogously to the procedure described in example 1 c) by reacting R,R-N-(2-aminocyclohexyl)-N'-(4-methyl-3-thienyl)thiourea and methyl iodide in anhydrous ethanol as solvent and reaction medium. Amorphous precipitate which is chromatographed on silica gel using mixture 4 as mobile phase and crystallized under acetone. Crystalline solid, m.p. 235-2380C.
Example 11: trans-S,S-3N-(3a,4,5,6,7,7a-Hexahydro-1 H-2-benzimidazolyl)- 4-methyl-3-thienylamine hydrochloride x HCI a) trans-S,S-3N-(2-Aminocyclohexyl)-N'-(4-methyl-3-thienyl)thiourea is obtained analogously to the reaction described in example 1 b) from 4-methyl- 3-thienyl isothiocyanate and trans-S,S-1,2-diaminocyclohexane by separation by silica gel column chromatography using mixture 4 as mobile phase, as an amorphous oily product in addition to a product of higher molecular weight of m.p. 94-1020C.
The amorphous product is processed further without further purification.
b) trans-S,S-N-(3a,4,5,6,7,7a-Hexahydro- 1H-2-benzimidazolyl)-4-methyl- 3-thienylamine hydrochloride is obtained analogously to the procedure described in example 1 c) by reacting S,S-N-(2-aminocyclohexyl)-N'-(4-methyl-3-thienyl)thiourea and methyl iodide in anhydrous ethanol as solvent and reaction medium. Amorphous precipitate which is chromatographed on silica gel using mixture 4 as mobile phase and crystallizes under acetone. Crystalline solid, m.p. 225-230 0
C.
Example 12: 2-Chloro-3N-(2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and 2,5-dichloro-3N-(2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HCI x HCI C cIS C are obtained analogously to the procedure described in example 2 from 3N-(2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and N-chlorosuccinimide in glacial acetic acid. Column chromatography on silica gel using mixture 17 as mobile phase results in the separation of 2,5-dichloro-3N-(2-benzimidazolyl)-4-methyl- 3-thienylamine hydrochloride (colorless crystalline compound, 291 C) from 2-chloro-3N-(2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride (colorless crystalline compound, m.p. 257-259 0
C).
Example 13: 2-Chloro-3N-(4-methyl-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HCI -l CI S is obtained analogously to the procedure described in example 2 from 3N-(4-methyl- 2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and N-chlorosuccinimide in glacial acetic acid. Following column chromatography on silica gel using mixture 17 as mobile phase, 2-chloro-3N-(4-methyl-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride is obtained as a colorless to slightly yellowish crystalline product.
M.p. 255-2590C.
Example 14: 2-Chloro-3N-(4,5,6,7-tetrafluoro-2-benzimidazolyl)-4-methyl- 3-thienylamine hydrochloride F x HCI
F
F CI S is obtained analogously to the procedure described in example 2: from 3N-(4,5,6,7-tetrafluoro-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and N-chlorosuccinimide in glacial acetic acid. Crystalline product. M.p. 233-235oC.
Example 15: trans-2-Chloro-3N-(3a,4,5,6,7,7a-hexahydro- 1 H-2-benzimidazolyl)- 4-methyl-3-thienylamine hydrochloride (racemate) x HCI CI S is obtained analogously to the procedure described in example 2: from 3N-(3a,4,5,6,7,7a-hexahydro- 1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride (racemate) and N-chlorosuccinimide in glacial acetic acid. Crystalline product. M.p. 258-2600C.
Example 16: trans- R, R-2-Chloro-3N-(3a,4,5,6,7,7a-hexahyd ro- 1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and trans- R, 3N-(3a,4,5,6,7,7a-hexahydro- 1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HCI x HCI ci S CI S are obtained analogously to the procedure described in example 2: from trans- R, R-3N-(3a,4,5 ,6,7,7a-hexahydro- 1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and N-chlorosuccinimide in glacial acetic acid following chromatographic separation of the two crystalline products in the following order: a) trans- R, R-2,5-d ic hlIoro-3 N 4,5,6,7,7a- hexahyd ro- 1 H-2-benzimidazolyl)- 4-methyl-3-thienylamine hydrochloride, decomposition with foaming starting at 8000, b) trans- R, R-2-chloro-3N-(3a,4,5,6,7,7a-hexahyd ro- 1 H-2-benzimidazolyl)- 4-methyl-3-thienylamine hydrochloride, crystalline product. M 260-2620C.
Example 17: trans-S,S-2-Chloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HCI CI S is obtained analogously to the procedure described in example 2: from trans-S,S-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and N-chlorosuccinimide in glacial acetic acid following chromatographic separation. Colorless crystalline product, m.p. 258-2600C.
Example 18: 2-Bromo-3N-(2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and 2,5-dibromo-3N-(2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HCI x HCI N NBr B S B S are obtained analogously to the procedure described in example 2: from 3N-(2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and N-bromosuccinimide (instead of N-chlorosuccinimide) in glacial acetic acid. Following column chromatography on silica gel using a mixture of 5 parts of dichloromethane, 3 parts of n-heptane, 1 part of glacial acetic acid and 1 part of ethanol (hereinbelow referred to as "mixture as mobile phase and treatment with a solution of hydrogen chloride gas in ether, 2-bromo-3N-(2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride, a crystalline product of m.p. 228-231 C, and 2,5-dibromo-3N-(2-benzimidazolyl)- 4-methyl-3-thienylamine hydrochloride, a crystalline product of m.p. 208-210OC, are obtained by fractional crystallization in ethyl acetate.
Example 19: trans- R, R-2- Bromo-3N- (3a, 4,5,6,7,7a-h exa hyd ro- 1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and trans-R, 3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride x HCI x HCI H /\Br B S Br S are obtained analogously to the procedure described in example 18: from trans- R, R-3N-(3a,4,5,6,7,7a-hexahydro- 1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and N-bromosuccinimide in glacial acetic acid. Following column chromatography on silica gel using mixture 1 as mobile phase, and treatment with a solution of hydrogen chloride gas in ether, trans-R,R-2-bromo- 3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride, crystalline product, m.p. 215-2180C and trans- R, 3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride, crystalline product, m.p. 218-2200C are obtained following fractional crystallization in ethyl acetate.
Example 20: 3N-(4-Chloro-2-benzimidazolylamino)-4-methylthiophene hydrochloride CI x HCI 'N
H
N
H
S
a) N-(2-Amino-3-chlorophenyl)-N'-(4-methyl-3-thienyl)thiourea is obtained analogously to the reaction described in example 1 b) from 4-methyl-3thienyl isothiocyanate and 3-chloro-1,2-diaminobenzene (prepared by catalytic hydrogenation of 3-chloro-2-nitroaniline using Pt on activated carbon under atmospheric pressure at room -temperature). Crystalline solid, m.p. 298-3050C, b) 3N-(4-Chloro-2-benzimidazolylamino)-4-methylthiophene hydrochloride is obtained analogously to the procedure described in example 1 c) from N-(2-amino-3chlorophenyl)-N'-(4-methyl-3-thienyl)-thiourea and methyl iodide. Amorphous precipitate which crystallizes under ethyl acetate. Crystalline solid, point of decomposition 240-245°C Example 21: 2-Chloro-3N-(4-chloro-2-benzimidazolylamino)-4-methylthiophene hydrochloride CI x HCI KN
H
CI S is obtained analogously to the procedure described in example 2 from 3N-(4-chloro-2benzimidazolyl)-4-methyl-3-thienylamine hydrochloride and N-chlorosuccinimide in glacial acetic acid. Following silica gel column chromatography using a mixture of parts of methylene chloride and 1 part of methanol as mobile phase, 2-chloro-3N- (4-chloro-2-benzimidazolylamino)-4-methylthiophene hydrochloride is, after crystallization under ethyl acetate, obtained as a colorless to slightly yellowish solid.
M.p. 270-272oC.
Example 22: 2-Bromo-3N-(4-chloro-2-benzimidazolylamino)-4-methylthiophene hydrochloride CI x HCI Br S is obtained analogously to the procedure described in example 2 from 3N-(4-chloro- 2-benzimidazolylamino)-4-methylthiophene hydrochloride and N-bromosuccinimide (instead of N-chlorosuccinimide) in glacial acetic acid. Following silica gel column chromatography using a mixture of 20 parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid as mobile phase and treatment with a solution of hydrogen chloride gas in ether, 2-bromo-3N-(4-chloro-2-benzimidazolylamino)-4methylthiophene hydrochloride is obtained by fractionated crystallization in ethyl acetate in the presence of hydrogen-chloride-saturated ether. Crystalline product of m.p. 278-280°C Example 23: (2-Bromo-4-methylthiophene-3-yl)-(5-fluoro-1H-benzoimidazol-2-yl)amine F N H xHCI Br hydrochloride
S
(5-Fluoro-1H-benzimidazol-2-yl)-(4-methylthiophene-3-yl)amine (300 mg) (example 1) was dissolved in glacial acetic acid (50 ml). At room temperature, N-bromosuccinimide (207 mg) dissolved in glacial acetic acid (10 ml), was slowly added dropwise, with vigorous stirring. After the addition had ended, stirring was continued for another min and the glacial acetic acid was then distilled off under reduced pressure, and the residue was dissolved in ethyl acetate and washed with saturated potassium carbonate solution. The organic phase was dried over magnesium sulfate, filtered and concentrated. The residue was purified by preparative chromatography and the product-containing fractions were combined, freed from acetonitrile, made basic and extracted three times with ethyl acetate. The organic phases were combined, dried (MgSO4) and filtered. Following removal of the solvent under reduced pressure, water and 2N hydrochloric acid were added to the residue and the mixture was freeze-dried.
This gave 245 mg of the desired product.
LCMS-Rt 0.95 min MS (ES 326.09 Example 24: 2-Bromo-3N-(4-fluoro-2-benzimidazolylamino)-4-methylthiophene hydrochloride and 2,5-dibromo-3N-(4-fluoro-2-benzimidazolylamino)-4-methylthiophene hydrochloride F xHCI F xHCI N and N H H Br Br S Br S A solution of 0.161 g of N-bromosuccinimide in 6 ml of glacial acetic acid is added to a solution of 0.214 g of 3N-(4-fluoro-2-benzimidazolylamino)-4-methylthiophene hydrochloride in 6 ml of glacial acetic acid, and the mixture is stirred at room temperature for 30 minutes. After removal of the solvent by distillation, water is added to the residue and the mixture is made alkaline using 2N NaOH and extracted with ethyl acetate. The organic phase is dried, the solvent is distilled off and the residue is separated by silica gel column chromatography using a mixture of 20 parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid. The hydrochlorides of the two compounds are obtained by distilling off the fractionated solutions, dissolving the residue in ethyl acetate and precipitating the product by addition of hydrogenchloride-saturated diethyl ether. Crystallization was promoted by gentle warming.
Example 24a: 2-Bromo-3N-(4-fluoro-2-benzimidazolylamino)-4-methylthiophene hydrochloride: colorless crystals; m.p. 2120C (decomposition).
Example 24b: 2,5-Dibromo-3N-(4-fluoro-2-benzimidazolylamino)-4-methylthiophene hydrochloride: colorless crystals; m.p. 242-244oC (decomposition).
Example 25: 3N-(5-Methoxy-2-benzimidazolylamino)-4-methylthiophene
HC-O
a) N-(2-Amino-4-methoxyphenyl)-N'-(4-methyl-3-thienyl)thiourea A mixture of 5.89 g of 4-methylthiophene 3-isothiocyanate and 5 g of 4-methoxy- 1,2-diaminobenzene in 60 ml of anhydrous THF is stirred at room temperature for 2 hours, and the solvent is distilled off. Water is added to the residue, the mixture is extracted with ethyl acetate, the dark solution is treated with activated carbon and the organic solvent is re-evaporated. With gentle warming, the residue is treated repeatedly with diisopropyl ether and the solid is filtered off. Brown crystalline solid, m.p. 143-1460C.
b) A mixture of 2.83 g of N-(2-amino-4-methoxyphenyl)-N'-(4-methyl-3-thienyl)thiourea, g of methyl iodide and 100 ml of anhydrous ethanol is boiled under reflux for hours, and the solvent is then distilled off and water is added to the residue. Using 2N aqueous sodium hydroxide solution, the mixture is made alkaline and then extracted with ethyl acetate, the organic phase is treated with water and then with activated carbon and the product is purified by silica gel column chromatography using a mobile phase mixture of 20 parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid. This gives 3N-(5-methoxy-2-benzimidazolylamino)-4methylthiophene as an amorphous product.
Example 26: 3N-(5-Methoxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride x HCI
H
3 C-O
N
H is obtained by precipitating a solution of 0.2 g of 3N-(5-methoxy-2-benzimidazolylamino)-4-methylthiophene (example 25) in 10 ml of ethyl acetate using a saturated solution of hydrogen chloride gas and diethyl ether, giving a crystalline precipitate.
222-225°C Example 27: 2-Chloro-3N-(5-methoxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride x HCI HC-O\Q
N
H
CI S For about 2 to 2/2 hours, a mixture of 0.519 g of 3N-(5-methoxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride, 0.046g of N-chlorosuccinimide and 10-15 ml of glacial acetic acid is heated at 45°C. The glacial acetic acid is then distilled off, water is added to the residue and the mixture is adjusted to pH 9-10 using 2N NaOH.
The mixture is extracted with ethyl acetate, the solvent is evaporated and the residue is chromatographed on silica gel on a medium-pressure column using a mixture of parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid. The base obtained after removal of the solvent by distillation is, in ethyl acetate, converted into the hydrochloride using saturated etheral hydrogen chloride solution, and the product is crystallized under ethyl acetate. Crystalline solid 182-186°C.
Example 28: 2,5-Dichloro-3N-(5-methoxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride x HCI H 3 C-O N H
CI
CI S Analogous work-up of a reaction mixture of 3N-(5-methoxy-2-benzimidazolylamino)-4methylthiophene hydrochloride, N-chlorosuccinimide and glacial acetic acid for about 2 to 21/2 hours at 550C gave 2,5-dichloro-3N-(5-methoxy-2-benzimidazolylamino)- 4-methylthiophene. Crystalline solid, 278-2820C.
Example 29: 3N-(4-Methoxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride 3 0 x HCI N N H
-S
a) 3-Methoxy-1,2-diaminobenzene was obtained as a brown oil by hydrogenation of 2-methoxy-6-nitroaniline using hydrogen gas and Raney nickel as catalyst at room temperature and a pressure of 3 bar. The product was converted into the thiourea without further purification.
b) N-(2-Amino-3-methoxyphenyl)-N'-(4-methyl-3-thienyl)thiourea is obtained analogously to the procedure described in example 25 a) from 3-methoxy- 1,2-diaminobenzene and 4-methyl-3-thienyl isothiocyanate in anhydrous THF, followed by medium-pressure chromatography on silica gel using a mixture of 1 part of toluene and 1 part of ethyl acetate. Crystalline solid, 148-153oC. Solidification of the melt and next m.p. at 2600C.
c) 3N-(4-Methoxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride is obtained analogously to the procedures described in examples 25 and 26 from N-(2-amino-3-methoxyphenyl)-N'-(4-methyl-3-thienyl)thiourea by heating with methyl iodide in THF, analogous work-up and treatment of the benzimidazole with HCI in ether.
Crystalline solid, 230-2350C.
Example 30: 2-Chloro-3N-(4-methoxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride x HCI
H
CI S A mixture of 0.1 g of 3N-(4-methoxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride, 0.046 g of N-chlorosuccinimide and 10-15 ml of glacial acetic acid is heated at 40°C for about 2 to 2V2 hours. The glacial acetic acid is then distilled off, water is added to the residue and the pH is adjusted to 9-10 using 2N NaOH. The mixture is extracted with ethyl acetate, the solvent is evaporated and the residue is chromatographed on silica gel on a medium-pressure column using a mixture of parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid. The resulting base is, in ethyl acetate, converted into the hydrochloride using saturated etheral hydrogen chloride solution. Colorless to light-yellow crystalline solid, m.p.: 248-2500C.
Example 31: 3N-(4-Chloro-6-trifluoromethyl-2-benzimidazolylamino)-4-methylthiophene hydrochloride CI x HCI FNC N a) N-(2-Amino-3-chloro-5-trifluoromethylphenyl)-N'-(4-methyl-3-thienyl)thiourea is obtained analogously to the procedure described in example 25 a) by reacting 3-chloro-5-trifluoromethyl-1,2-diaminobenzene and 4-methyl-3-thienyl isothiocyanate in anhydrous THF at room temperature for 3 days. The solvent is distilled off and water is added to the residue, and the mixture is then extracted with ethyl acetate, the solvent is again distilled off and the amorphous residue is crystallized under diisopropyl ether.
310°C.
b) 3N-(4-chloro-6-trifluoromethyl-2-benzimidazolylamino)-4-methylthiophene hydrochloride is obtained analogously to the procedures described under examples 25 and 26 from N-(2-amino-3-chloro-5-trifluoromethylphenyl)-N'-(4-methyl-3-thienyl)thiourea by boiling with methyl iodide in THF under reflux conditions for 5 hours, analogous work-up and purification by medium-pressure silica gel column chromatography using a mixture of identical parts by volume of ethyl acetate and toluene. The solvent is evaporated and the residue is then dissolved in ethyl acetate, giving, by addition of a saturated solution of hydrogen chloride in diethyl ether, 3N-(4-chloro-6-trifluoromethyl-2-benzimidazolylamino)-4-methylthiophene hydrochloride as a crystalline precipitate. Solid, 210- 213°C.
Example 32: 2-Chloro-3N-(4-chloro-6-trifluoromethyl-2-benzimidazolylamino)- 4-methylthiophene hydrochloride CI x HCI 'N H
A
CI S A mixture of 0.34 g of 3N-(4-methoxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride, 0.151 g of N-chlorosuccinimide and 20 ml of glacial acetic acid is stirred at room temperature for /2 hour and heated at 60°C for one hour. The glacial acetic acid is then distilled off, water is added to the residue and the pH is adjusted to 9-10 using 2N NaOH. The mixture is extracted with ethyl acetate, the solvent is evaporated and the residue is chromatographed on silica gel on a medium-pressure column using a mixture of identical parts of toluene and ethyl acetate. The solvent is distilled off and the resulting base is then, in ethyl acetate, converted into the hydrochloride using saturated etheral hydrogen chloride solution,. Colorless to light-yellow crystalline solid.
mp.: 247-2500C.
Example 33: 3N-(4-Carboxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride OOH x HCI
N
H
S
a) N-(2-Amino-3-carboxyphenyl)-N'-(4-methyl-3-thienyl)thiourea is obtained analogously to the procedure described in example 25 a) from 3-carboxy- 1,2-diaminobenzene and 4-methyl-3-thienyl isothiocyanate in anhydrous THF, followed by medium-pressure chromatography on silica gel using a mixture of 12 parts of methylene chloride and 1 part of methanol. Amorphous product.
b) 3N-(4-Carboxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride is obtained by boiling a solution of 1.12 g of N-(2-amino-3-carboxyphenyl)- N'-(4-methyl-3-thienyl)thiourea and 3.1 g of methyl iodide in 60 ml of ethanol under reflux. The solvent is evaporated, water is added to the residue, the pH is adjusted to using 2N aqueous HCI and the precipitate is filtered off. Crystalline solid, point of decomposition: 265-285oC.
Example 34: 2-Chloro-3N-(4-carboxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride OOH x HCI SN H
N
H
CI S is obtained analogously to the procedure described in example 32 from 0.2 g of 3N- (4-carboxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride and 0.103 g of N-chlorosuccinimide in 20-25 ml of glacial acetic acid and precipitation of the corresponding hydrochloride using HCI-saturated diethyl ether in ethyl acetate and subsequent crystallization under diisopropyl ether and ethyl acetate. Point of decomposition 170 0
C.
Example 35: 3N-[4-(1-Piperidinocarbonyl)-2-benzimidazolylamino]-4-methylthiophene hydrochloride N xHC
I
N
H
H
S
0.215g of N,N'-carbonyldiimidazole is added to a mixture of 0.330 g of 3N-(4-carboxy- 2-benzimidazolylamino)-4-methylthiophene hydrochloride, 30 ml of anhydrous THF and 5 ml of anhydrous dimethylacetamide. The mixture is stirred at room temperature
I
for about 4 hours, when the evolution of carbon dioxide has ceased, and 0.411 g of piperidine is then added. The solution is stirred at room temperature for 2 hours and, after standing overnight, the solvent is distilled off under reduced pressure. The residue is triturated with water, the solid is filtered off and dissolved in ethyl acetate, the insoluble fraction is removed by filtration and the solvent is distilled off under reduced pressure. Foam-like amorphous product.
Example 36: 2-Chloro-4-methyl-3N-[4-(1-piperidinocarbonyl)-2-benzimidazolylamino]thiophene hydrochloride 0,x
HCI
N>"-N
H
CI S A mixture of 0.2 g of 3N-[4-(1-piperidinocarbonyl)-2-benzimidazolylamino]-4-methylthiophene hydrochloride and 0.086g of N-chlorosuccinimide in about 20 ml of glacial acetic acid is stirred at room temperature for 11/2 hours and at 350C for about 30 min, the solvent is distilled off and the residue is, after addition of water, made alkaline using 2N NaOH. Following extraction with ethyl acetate, the solvent is evaporated and the residue is purified by medium-pressure silica gel column chromatography using a mixture of 20 parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid. The solvent is distilled off, the residue is dissolved in ethyl acetate and the mixture is acidified using a solution of ether saturated with hydrogen chloride. The amorphous residue is crystallized under a mixture of ethyl acetate with a little acetone and a little ethanol. Amorphous solid, point of decomposition from 100C.
Example 37: 2-Chloro-3N-(4-fluoro-2-benzimidazolylamino)-4-methylthiophene hydrochloride
F
F x HCI N
H
H
CI S 0.132 g of N-chlorosuccinimide is added to 0.234 g of 3N-(4-fluoro-2-benzimidazolylamino)-4-methylthiophene hydrochloride in about 20 ml of glacial acetic acid and the mixture is stirred at room temperature for 30 minutes and at 50-60°C for another 11/2 hours. The acetic acid is distilled off under reduced pressure, water is then added to the residue and the pH is adjusted to about 10-11 using 2N NaOH, and the mixture is extracted with ethyl acetate, which is then distilled off. The residue is chromatographed on a silica gel column under medium-pressure conditions using a mixture of 20 parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid. After concentration, the residue is dissolved in a little ethyl acetate and the hydrochloride is precipitated by addition of hydrogen-chloride-saturated diethyl ether.
Colorless to light-yellow crystalline solid. 268-2700C.
Example 38: 2-Chloro-3N-(4-hydroxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride Nx HCI >N H
N
H
CI S A suspension of 0.13 g of 2-chloro-3N-(4-methoxy-2-benzimidazolylamino)-4-methylthiophene hydrochloride in about 20 ml of anhydrous methylene chloride is added to a suspension of 0.29 g of activated anhydrous aluminum chloride in 10 ml of anhydrous methylene chloride, and the reaction mixture is stirred at 55 0 C for 2 hours. After cooling, the reaction mixture is poured into ice-water and extracted with ethyl acetate, the organic phase is dried over sodium sulfate and the solvent is distilled off. The residue is chromatographed on a silica gel column under medium-pressure conditions using a mixture of 20 parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid, and the eluate is concentrated under reduced pressure. The residue is dissolved in ethyl acetate and the hydrochloride is precipitated by addition of hydrogen-chloride-saturated diethyl ether. Crystalline solid. M.p. 246-2480C.
Example 39: 2-Chloro-3N-(2-benzimidazolylamino)-4-methylthiophene
H
CI S is obtained by adding 2N NaOH to a solution of 3 g of 2-chloro-3N-(2-benzimidazolylamino)-4-methylthiophene hydrochloride in 200 ml of water until a pH of 10 is set. The crystals are filtered off and washed repeatedly with water. Yield: 2.52 g. Colorless crystal powder. M.p. 182-185 0
C.
Example 40: 2-Chloro-3N-(2-benzimidazolylamino)-4-methylthiophene hydrobromide x HBr
N
H I' CI S 0.25 g of 2-chloro-3N-(2-benzimidazolylamino)-4-methylthiophene is dissolved in 10 ml of ethanol, 0.1 ml of 48% strength HBr is then added and the mixture is stirred at room temperature for a little while. The solvent is distilled off and the residue is crystallized under ethyl acetate. Yield: 0.29 g. Colorless crystals, point of decomposition: 252-254 0
C.
Example 41: 2-Chloro-3N-(2-benzimidazolylamino)-4-methylthiophene adipic acid salt N x HOOCCOOH HN XH
H
CI S is obtained analogously to the procedure described in example 40 from 2-chloro-3N- (2-benzimidazolylamino)-4-methylthiophene using one equivalent of adipic acid.
Colorless crystals. M.p. 155-1570C.
Example 42: 2-Chloro-3N-(2-benzimidazolylamino)-4-methylthiophene oxalic acid salt S N x HOOC H CI S is obtained analogously to the procedure described in example 40 by reacting 2-chloro-3N-(2-benzimidazolylamino)-4-methylthiophene with one equivalent of oxalic acid in ethyl acetate. Colorless crystals. 220-222oC.
Example 43: 2-Chloro-3N-(2-benzimidazolylamino)-4-methylthiophene phosphoric acid salt H N x H 3
PO
4 H CI S is obtained analogously to the procedure described in example 40 from 2-chloro-3N- (2-benzimidazolylamino)-4-methylthiophene using one equivalent of phosphoric acid.
Colorless crystals. Decomposition range: 113-1750C.
Example 44: (1 H-Benzimidazol-2-yl)-(2-chloro-4-methylthiophen-3-yl)methylamine 0 N N
H
Finely powdered dry potassium carbonate (66 mg) was added to a solution of 2-chloro- 3N-(2-benzimidazolyl)-4-methyl-3-thienylamine (125 mg, from example 39) and dry methanol (20 ml). Methyl iodide (74 mg) was then added dropwise with exclusion of moisture and vigorous stirring, and the mixture was kept under reflux for three days.
The solvent was removed under reduced pressure and the residue was then partitioned between ethyl acetate and water, the ethyl acetate phase was dried with magnesium sulfate, the magnesium sulfate was filtered off and the filtrate was evaporated to dryness. The product was then purified by preparative HPLC. The product-containing fractions were combined and, after removing the acetonitrile under reduced pressure, freeze-dried. For further purification, the product was finally chromatographed on silica gel using ethyl acetate/heptane The productcontaining fractions were combined and then evaporated to dryness, and the residue was taken up in HCI and freeze-dried. This gave 5 mg of a solid.
LCMS-Rt 2.04 min MS (ES 278.05 Example 45: (5,6-Difluoro-1 H-benzimidazol-2-yl)-(4-methylthiophen-3-yl)amine trifluoroacetic acid salt F N x CF 3
-COOH
SI F N
S
3-lsothiocyanato-4-methylthiophene (1.08 dissolved in absolute tetrahydrofuran ml), was added dropwise to a solution of 1,2-diamino-4,5-difluorobenzene (1 g in absolute tetrahydrofuran (20 ml). The mixture was then stirred at room temperature for 2 hours and allowed to stand overnight. Methyl iodide (0.44 ml) was added and the mixture was then stirred for 8 hours and allowed to stand overnight. The tetrahydrofuran was then removed under reduced pressure, the residue was partitioned between ethyl acetate and water, the phases were separated and the ethyl acetate phase was dried over magnesium sulfate. The residue was absorbed under silica gel and chromatographed on silica gel using the mobile phase n-heptane ethyl acetate 1:1.
This gave 229 mg of the desired compound as the free base.
An impure fraction from the above chromatography was purified by preparative HPLC.
Following freeze-drying, 42.2 mg of the desired compound were isolated as trifluoroacetic acid salt.
LCMS-Rt 1.98 min MS (ES 266.13 Example 46: (2-Chloro-4-methylthiophen-3-yl)-(5,6-difluoro-1 H-benzoimidazol- 2-yl)amine hydrochloride FN H x HCI F N H
H
S
At room temperature, a solution of N-chlorosuccinimide (124.6 mg) in glacial acetic acid (5 ml) was added dropwise to a solution of (5,6-difluoro-1H-benzimidazol-2-yl)-(4methylthiophen-3-yl)amine (225 mg) in glacial acetic acid (5 ml). The mixture was then stirred at room temperature for 3.5 hours. The glacial acetic acid was then removed and the residue was taken up in water and adjusted to pH 10 using 2 M aqueous sodium hydroxide solution. The aqueous phase was extracted three times with ethyl acetate, the combined organic phases were dried over magnesium sulfate and the solvent was removed. The residue was purified by preparative chromatography and the product-containing fractions were combined, freed from acetonitrile, made basic and extracted three times with ethyl acetate. The organic phases were combined, dried (MgSO4), filtered and concentrated. The residue was taken up in water, acidified with strength hydrochloric acid and freeze-dried. This gave 81 mg of the desired product as a solid.
LCMS-Rt 2.15 min MS (ES 300.11 Example 47: (2-Bromo-4-methylthiophen-3-yl)-(5,6-difluoro-1 H-benzoimidazol-2-yl)amine
H
At room temperature, a solution of N-bromosuccinimide (8 mg) in glacial acetic acid ml) was added dropwise to a solution of (5,6-difluoro-1 H-benzimidazol-2-yl)- (4-methylthiophen-3-yl)amine trifluoroacetic acid salt (15 mg, example 45) in glacial acetic acid (0.5 ml) in a ReactiVial, and the mixture was stirred at room temperature for h. The acetic acid was then removed under reduced pressure and saturated potassium carbonate solution and ethyl acetate were added to the residue. The organic phase was removed and the aqueous phase was then extracted twice with ethyl acetate. The combined organic phases were dried using magnesium sulfate and the drying agent was then filtered off. The residue that remained after removal of the solvent under reduced pressure was purified by preparative chromatography. The product-containing fractions were combined and freed from acetonitrile, saturated sodium bicarbonate solution was added to the residue and the mixture was extracted three times with ethyl acetate. The organic phases were combined, dried (MgSO4) and filtered. After removal of the ethyl acetate under reduced pressure, the residue was coevaporated with toluene and then dried under high vacuum. This gave 8.1 mg of the desired compound.
LCMS-Rt 1.45 min MS 343.96 Example 48: [(2-Chloro-4-methylthiophen-3-yl)-(4,5,6,7-tetrahydro-1 H-benzimidazol-2yl)]amine hydrochloride a) 1,4-Dioxaspiro[4.5]dec-6-ylamine
H
2
N
0 0 The amine required as precursor was prepared in accordance with GB1131191.
2-Chlorocyclohexanone was reacted with phthalimide to give 2-(2-oxocyclohexyl)isoindole-1,3-dione, which was ketalized with ethylene glycol in the presence of para-toluenesulfonic acid, giving 2-(1,4-dioxaspiro[4.5]dec-6-yl)isoindole-1,3-dione.
Treatment with hydrazine hydrate to remove the phthalimideradical gave the desired 1,4-dioxaspiro[4.5]dec-6-ylamine.
b) 1-(1,4-Dioxaspiro[4.5]dec-6-yl)-3-(4-methylthiophen-3-yl)thiourea S
S
S N N H H O 0 A solution of 3-isothiocyanato-4-methylthiophene (296.2 mg, see example la) in absolute tetrahydrofuran (10 ml) was added dropwise to a solution of 1,4-dioxaspiro[4.5]dec-6-ylamine (300 mg) in absolute tetrahydrofuran (10 ml), the mixture was stirred at room temperature for 2 hours and the solvent was then removed under reduced pressure. The residue was purified by preparative chromatography and the product-containing fractions were combined, freed from acetonitrile, made basic and extracted three times with ethyl acetate. The organic phases were combined, dried (MgS04) and filtered. This gave 428 mg of the desired product.
LCMS-Rt 3.57 min MS (ES 313.19 c) 1-(1,4-Dioxaspiro[4.5]dec-6-yl)-2-methyl-3-(4-methylthiophen-3-yl)isothiourea S N N H O" 1-(1,4-Dioxaspiro[4.5]dec-6-yl)-3-(4-methylthiophen-3-yl)thiourea (393 mg) was dissolved in absolute tetrahydrofuran (8.5 ml), and a solution of methyl iodide (179 mg) in absolute tetrahydrofuran (0.5 ml) was added. The mixture was then stirred at in sand bath for 2 days. Ethyl acetate was then added to the reaction mixture, and the mixture was washed twice with water. The organic phase was dried over magnesium sulfate and the solvent was removed after filtration. The residue was purified by preparative chromatography and the product-containing fractions were combined, freed from acetonitrile, made basic and extracted three times with ethyl acetate. The organic phases were combined, dried (MgSO4) and filtered. This gave 59 mg of the desired product which was used directly for the next step.
LCMS-Rt 1.05 min MS (ES 327.4 d) N-(1,4-Dioxaspiro[4.5]dec-6-yl)-N'-(4-methylthiophen-3-yl)guanidine NS N H O In a ReactiVial, a 7 M solution of ammonia in methanol (2 ml) was added to 1- (1,4-dioxaspiro[4.5]dec-6-yl)-2-methyl-3-(4-methylthiophen-3-yl)isothiourea (58.8 mg), and the mixture was heated in a sand bath at about 100°C for 16 hours. Removal of the solvent gave a residue of 51 mg of an oily product which was directly reacted further.
LCMS-Rt 1.00 min MS (ES 296.4 e) N-(2-Chloro-4-methylthiophen-3-yl)-N'-(1,4-dioxaspiro[4.5]dec-6-yl)guanidine S NH
S
N; N CI H 0 N-(1,4-Dioxaspiro[4.5]dec-6-yl)-N'-(4-methylthiophen-3-yl)guanidine (49 mg) was dissolved in glacial acetic acid (3 ml), and a solution of N-chlorosuccinimide (20.3 mg) in glacial acetic acid (5 ml) was added slowly. The mixture was stirred for a number of hours and then allowed to stand at room temperature over the weekend, after which the glacial acetic acid was removed under reduced pressure, the residue was taken up in water and the mixture was adjusted to pH 10 using 2N sodium hydroxide solution.
The basic phase was extracted three times with ethyl acetate and the combined organic phases were dried over magnesium sulfate, filtered and concentrated. The residue was purified by preparative chromatography and the product-containing fractions were combined, freed from acetonitrile, made basic and extracted three times with ethyl acetate. The organic phases were combined, dried (MgSO4) and filtered.
Removal of the solvent under reduced pressure gave 24 mg of the desired product which was used directly for the next step.
LCMS-Rt 1.09 min MS (ES 330.4 f) ((2-Chloro-4-methylthiophen-3-yl)-(4,5,6,7-tetrahydro-1 H-benzoimidazol-2-yl))amine hydrochloride
S
r N ci H HH HCI N-(2-Chloro-4-methylthiophen-3-yl)-N'-(1,4-dioxaspiro[4.5]dec-6-yl)guanidine (24 mg) was dissolved in 2N hydrochloric acid (1 ml) and stirred at room temperature for 30 min. Concentrated hydrochloric acid (1 ml) was then added, and the mixture was stirred for another two hours. The mixture was then diluted with a little water and freeze-dried. Toluene was added to the residue and then distilled off under reduced pressure. This step was repeated twice, giving 22 mg of the desired product as a solid.
LCMS-Rt 0.95 min MS (ES 268.07 Example 49: 2-Chloro-3N-(2-benzimidazolylamino)-4-methylthiophene benzenesulfonate HO O H ^0 0
H
CIl 2-Chloro-3N-(2-benzimidazolylamino)-4-methylthiophene (250 mg) was dissolved in THF (5 ml), and benzenesulfonic acid (150 mg), dissolved in THF (5 ml), was added with stirring. After 3 h, the reaction mixture was left in the fridge overnight. The precipitate was filtered off with suction and dried at 75 0 C under high vacuum, giving the desired product. Colorless crystals. 2350C Example 50: 2-Chloro-3N-(2-benzimidazolylamino)-4-methylthiophene methanesulfonate o o Q
HO
H
was obtained analogously to the procedure described in example 49 from 2-chloro- 3N-(2-benzimidazolylamino)-4-methylthiophene using one equivalent of methanesulfonic acid. Colorless crystals. 227°C Example 51: 2-Chloro-3N-(2-benzimidazolylamino)-4-methylthiophene benzoate
H
:N
H I cil s was obtained analogously to the procedure described in example 49 from 2-chloro-3N- (2-benzimidazolylamino)-4-methylthiophene using one equivalent of benzoic acid. For the precipitation, the reaction mixture was concentrated to half of its original volume, and ether (30 ml) was then added. Colorless crystals, 198°C Example 52: 2,4-Dichloro-3N-(2-benzimidazolylamino)thiophene hydrochloride x HCI
N
H
CI S a) Methyl 3-acetylaminothiophene 2-carboxylate With simultaneous heating in an oil bath, 567 ml of acetic anhydride are added dropwise to a mixture of 942 g of methyl 3-aminothiophene-2-carboxylate and 1 000 ml of toluene, and the mixture is then boiled under reflux conditions for 1/2 hours and subsequently cooled in an ice bath to about 0°C. The crystals are filtered off and washed twice with a little isopropanol and twice with diisopropyl ether. Methyl 3acetylaminothiophene-2-carboxylate can be obtained from the filtrate by further concentration and crystallization. M.p. 93-950C.
b) Methyl 3-acetylamino-4,5-dichlorothiophene-2-carboxylate With magnetic stirring at a reaction temperature of 20-300C, 17.9 g of sulfuryl chloride S0 2 C1 2 are added dropwise to a solution of 19.9 g of methyl 3-acetylaminothiophene-2carboxylate in 100 ml of chloroform. The mixture is then stirred at 40°C for another 2 hours and boiled under reflux conditions for another 15 minutes. The solvent is distilled off under reduced pressure, ethyl acetate is then added to the residue and the crystals are, after standing, filtered off. M.p. 136-138°C.
c) Methyl 3-acetylamino-4 chlorothiophene-2-carboxylate A mixture of 25 g of methyl 3-acetylamino-4,5-dichlorothiophene-2-carboxylate, about 10 g of triethylamine, 300 ml of methanol and 1 g of palladium on carbon is, at room temperature and under atmospheric pressure, hydrogenated until the uptake of hydrogen has stopped. The catalyst is filtered off and the mixture is then concentrated by distillation under reduced pressure until crystallization begins, water is then added and the solid is filtered off. Colorless crystals from isopropanol. M.p. 142-1470C.
d) Methyl 3-amino-4-chlorothiophene-2-carboxylate In a mixture of 50 ml of methanol and 50 ml of concentrated hydrochloric acid, 7 g of methyl 3-acetylamino-4-chlorothiophene-2-carboxylate are stirred at 60°C for 4 hours, under reflux for 5 hours and at room temperature for another 3 days. Any precipitate that has formed is removed by filtration, and about 1/3 of the volume of the solvent is removed by distillation under reduced pressure. Following addition of about 100 ml of water, the mixture is stirred at room temperature for another 15 minutes and the colorless crystals are filtered off and dried in a stream of air. 62-64oC.
e) 3-Amino-4-chlorothiophene 18.02 g of methyl 3-amino-4-chlorothiophene-2-carboxylate are added to a solution of 11.1 g of KOH and 160 ml of water and the mixture is then boiled under reflux for 3 hours and, after cooling, added dropwise to a solution, which is at 60°C, of 15 ml of concentrated hydrochloric acid and 30 ml of water. This results in a vigorous evolution of CO2. After further stirring at 60°C for about 40 minutes, the mixture is allowed to cool, a layer of 50-100 ml of methyl tert-butyl ether is added, the mixture is made alkaline using concentrated aqueous sodium hydroxide solution and the aqueous phase is extracted in a separating funnel. The aqueous phase is extracted two more times with methyl tert-butyl ether, and the combined organic extracts are washed once with water in a separating funnel. The organic phase is dried, the solvent is distilled off and the oily-amorphous residue is chromatographed on a silica gel column using a mixture of 1 part of ethyl acetate and 1 part of toluene.
r f) 4-Chloro-3-thienyl isothiocyanate 1.46 g of thiocarbonyldiimidazole are added to a solution of 1.1 g of 3-amino-4chlorothiophene in 20 ml of anhydrous THF, and the mixture is stirred at room temperature for one hour. The solid is distilled off under reduced pressure, the residue is dissolved in ethyl acetate, the organic phase is treated twice with water in a separating funnel and then dried, and the solvent is again distilled off under reduced pressure. This gives 4-chloro-3-thienyl isothiocyanate as a dark oil which is then reacted further without further purification steps.
g) N-(2-Aminophenyl)-N'-(4-chloro-3-thienyl)thiourea 0.86 g of 1,2-diaminobenzene (o-phenylenediamine) is added to a solution of 1.4 g of 4-chloro-3-thienyl isothiocyanate in 40 ml of anhydrous THF, the mixture is stirred at room temperature for about 20 hours and the solvent is distilled off under reduced pressure. The residue is treated with water and extracted with ethyl acetate, the solvent is distilled off again and the residue is purified using medium-pressure silica gel column chromatography using a 1:1 mixture of ethyl acetate and toluene. Brownyellow solid.
h) 4-Chloro-3N-(2-benzimidazolylamino)thiophene A solution of 0.169 g of sodium hydroxide in 5 ml of water, followed by a solution of 0.363 g of p-toluenesulfonyl chloride in 10 ml of THF, is added to a solution of 0.5 g of N-(2-aminophenyl)-N'-(4-chloro-3-thienyl)thiourea in 25 ml of anhydrous THF. The mixture is stirred at room temperature for 3 hours, the solvent is then distilled off under reduced pressure and the residue is treated with water and extracted with ethyl acetate. After removal of the solvent by distillation, the product is purified by mediumpressure silica gel chromatography using a mixture of 20 parts of ethyl acetate, parts of n-heptane and 3 parts of glacial acetic acid as eluent.
For characterization, a small portion of the 4-chloro-3N-(2-benzimidazolylamino)thiophene was, in ethyl acetate, using ethereal hydrogen chloride solution, converted into 4-chloro-3N-(2-benzimidazolylamino)thiophene hydrochloride and characterized.
Colorless crystals. 256-2600C.
i) 2,4-Dichloro-3N-(2-benzimidazolylamino)thiophene hydrochloride A solution of 0.16 g of N-chlorosuccinimide in 5 ml of glacial acetic acid is added to a solution of 0.3 g of 4-chloro-3N-(2-benzimidazolylamino)thiophene in 10 ml of glacial acetic acid. The reaction mixture is stirred at 40°C for 15 minutes and at room temperature for about 4 hours, the acetic acid is then distilled off under reduced pressure and the residue is treated with water. The mixture is made alkaline using aqueous sodium hydroxide solution and then extracted with ethyl acetate, the extract is washed with water, the organic phase is dried and the solvent is distilled off under reduced pressure. The residue is purified under medium-pressure conditions by column chromatography using a mixture of 20 parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid as eluent and then precipitated from ethyl acetate by addition of a solution of hydrogen chloride in diethyl ether. Colorless crystalline product. M.p. 264-268°C.
Example 53: 2-Bromo-4-chloro-3N-(2-benzimidazolylamino)thiophene hydrochloride x HO H CI Br S A solution of 0.356 g of N-bromosuccinimide in 6 ml of glacial acetic acid is added dropwise to a solution of 0.5 g of 4-chloro-3N-(2-benzimidazolylamino)thiophene in ml of glacial acetic acid, and the mixture is stirred at room temperature for another minutes. The solvent is distilled off and the residue is treated with water and made alkaline using aqueous sodium hydroxide solution. Following extraction with ethyl acetate, the organic phase is washed with water, dried and concentrated under reduced pressure. The residue is chromatographed on silica gel using mediumpressure conditions and a mixture of 20 parts of ethyl acetate, 10 parts of n-heptane and 3 parts of glacial acetic acid as eluent. Following distillative removal of the solvent, the residue is taken up in ethyl acetate and 2-bromo-4-chloro-3N-(2-benzimidazolylamino)thiophene hydrochloride is precipitated by addition of a solution of hydrogen chloride gas in diethyl ether. Colorless crystalline product. 264-266°C.
Example 54: (2,4-Dichlorothiophen-3-yl)(5-fluoro-1 H-benzimidazol-2-yl)amine hydrochloride a) 1-(2-Amino-4-fluorophenyl)-3-(4-chlorothiophen-3-yl)thiourea NH H CI S S
F
4-Fluoro-1,2-phenylenediamine (900 mg) was dissolved in THF (25 ml), and 4-chloro- 3-thienyl isothiocyanate (example 52c), dissolved in THF (15 ml), was added dropwise with stirring. The solution was stirred at room temperature for about 3 hours and then allowed to stand overnight. The reaction mixture was then concentrated, and the residue was purified by preparative HPLC. The product-containing fractions were combined, freed from acetonitrile, made basic and extracted three times with ethyl acetate. The organic phases were combined, dried (MgSO4) and filtered. Removal of the solvent gave 625 mg of the desired product.
LCMS-Rt 1.28 min MS 302.0 b) (4-Chlorothiophen-3-yl)(5-fluoro-1 H-benzimidazol-2-yl)amine I N Cl
N
H
S
1-(2-Amino-4-fluorophenyl)-3-(4-chlorothiophen-3-yl)thiourea (625 mg) was dissolved in THF, and a solution of NaOH (0.207 g) in water (9 ml) was added. Over a period of min, a solution of p-toluyl chloride (0.395 g) in THF (10 ml) was added dropwise.
After the addition had ended, the mixture was stirred at room temperature for one hour.
For work-up, water and ethyl acetate were added to the reaction mixture, and the phases were separated in a separating funnel. The aqueous phase was extracted three times with ethyl acetate and the combined ethyl acetate phases were dried with magnesium sulfate, clarified with charcoal, filtered and concentrated. This gave 135 mg of the desired product.
LCMS-Rt 0.90 min MS (ES 268.0 c) (2,4-Dichlorothiophen-3-yl)(5-fluoro-lH-benzimidazol-2-yl)amine hydrochloride F
N
H
HCI Cl-_S (4-Chlorothiophen-3-yl)(5-fluoro-1 H-benzimidazol-2-yl)amine (85 mg) was dissolved in glacial acetic acid (4 ml), and N-chlorosuccinimide (42 mg), dissolved in glacial acetic acid (4 ml), was slowly added at room temperature, with vigorous stirring. After the addition had ended, the mixture was stirred at room temperature for 45 min and then at for 5 h. After the addition of further N-chlorosuccinimide (4 mg) stirring at was continued for one hour. Toluene (20 ml) was then added to the reaction mixture, and the glacial acetic acid was distilled off. The residue was dissolved in ethyl acetate and eluted using saturated potassium carbonate solution. The ethyl acetate phase was dried over magnesium sulfate, filtered and concentrated. The residue was purified by preparative HPLC and the product-containing fractions were combined, freed from acetonitrile, made basic and extracted three times with ethyl acetate. The organic phases were combined, dried (MgSO4) and filtered. After removal of the solvent, water and 2N hydrochloric acid were added to the residue, which was then freeze-dried. This gave 17 mg of the desired product.
LCMS-Rt 2.65 min MS (ES 301.93 Example 55: (2-Bromo-4-chlorothiophen-3-yl)(5-fluoro-1H-benzimidazol-2-yl)amine hydrochloride F N H
H
HCI Br
S
(4-Chlorothiophen-3-yl)(5-fluoro-1 H-benzimidazol-2-yl)amine (50 mg, example 54b) was dissolved in glacial acetic acid (4 ml), and N-bromosuccinimide (33 mg), dissolved in glacial acetic acid (4 ml), was slowly added at room temperature, with vigorous stirring. After the addition had ended, the mixture was stirred at room temperature for min, toluene (20 ml) was then added to the reaction mixture and the glacial acetic acid was distilled off. The residue was dissolved in ethyl acetate and washed with saturated potassium carbonate solution. The ethyl acetate phase was dried over magnesium sulfate, filtered and concentrated. The residue was purified by preparative chromatography and the product-containing fractions were combined, freed from acetonitrile, made basic and extracted three times with ethyl acetate. The organic phases were combined, dried (MgSO4) and filtered. After removal of the solvent, water and 2 N hydrochloric acid were added to the residue, which was then freeze-dried.
This gave 27 mg of the desired product.
LCMS-Rt 2.29 min MS (ES 347.87 Example 56: (2,4-Dichlorothiophen-3-yl)(5,6-difluoro-1H-benzimidazol-2-yl)amine hydrochloride a) 1-(2-Amino-4,5-difluorophenyl)-3-(4-chlorothiophen-3-yl)thiourea 1,2-Diamino-4,5-difluorobenzene (1.02 g) was initially charged in abs. THF (15 ml), and 4-chloro-3-thienyl isothiocyanate (1.25 g, example 52c), dissolved in abs. THF ml), was added dropwise. Further treatment analogously to example 54a) gave 773 mg of the desired compound.
LCMS-Rt 1.32 min MS 320.0 b) (4-Chlorothiophen-3-yl)(5,6-difluoro-1H-benzimidazol-2-yl)amine F N FN N F H
S
1-(2-Amino-4,5-difluorophenyl)-3-(4-chlorothiophen-3-yl)thiourea (773 mg) was initially charged in THF (20 ml), and a solution of NaOH (240 mg) in water (9 ml) followed by a solution of tosyl chloride (528 mg) in THF (10 ml) were added. Further treatment analogously to example 54b) gave 275 mg of the desired compound.
LCMS-Rt 0.95 min MS (ES 286 c) (2,4-Dichlorothiophen-3-yl)(5,6-difluoro-1 H-benzimidazol-2-yl)amine hydrochloride F N HCI Cl- S
S
(4-Chlorothiophen-3-yl)(5,6-difluoro-1 H-benzimidazol-2-yl)amine (125 mg) was initially charged in acetic acid (8 ml), and a solution of CI-succinimide (59 mg) in acetic acid (2 ml) was added dropwise. Further treatment analogously to example 54c) gave 58 mg of the desired product.
LCMS-Rt 2.97 min MS (ES 319.88 Example 57: (2-Bromo-4-chlorothiophen-3-yl)(5,6-difluoro-1H-benzimidazol-2-yl)amine hydrochloride F N N
C,
F H Br Br (4-Chlorothiophen-3-yl)(5,6-difluoro-1 H-benzimidazol-2-yl)amine (125 mg, example 55b) was dissolved in glacial acetic acid (8 ml), and N-bromosuccinimide (78 mg) dissolved in glacial acetic acid (2 ml), was slowly added at room temperature, with vigorous stirring. Further treatment analogously to example 55c) gave 77 mg of the desired product.
LCMS-Rt 2.39 min MS (ES 365.86 Example 58: 4-Chloro-3N-(4-methyl-2-benzimidazolylamino)thiophene hydrochloride x HCI
H
a) N-(2-Amino-3-methylphenyl)-N'-(4-chloro-3-thienyl)thiourea is obtained analogously to the procedure given in example 52g) from 4-chloro-3-thienyl isothiocyanate and 1,2-diamino-3-methylbenzene, using medium pressure column chromatography on silica gel with a mixture of 20 parts of ethyl acetate, 10 parts of n-heptane and 1 part of ethyl acetate. Brownish-yellow solid, 193-1960C.
b) e) 4-Chloro-3N-(4-methyl-2-benzimidazolylamino)thiophene is obtained analogously to the procedure given in example 52h) from N-(2-amino-3methylphenyl)-N'-(4-chloro-3-thienyl)thiourea using medium pressure column chromatography on silica gel with a mixture of 10 parts of dichloromethane and 1 part of methanol, as an amorphous, foam-like product. Preparation of the 4-chloro-3N-(4methyl-2-benzimidazolylamino)thiophene hydrochloride in ethyl acetate using diethyl ether saturated with hydrogen chloride gas. Crystalline product, m.p. 325-3270C.
Example 59: 2,4-Dichloro-3N-(4-methyl-2-benzimidazolylamino)thiophene hydrochloride x HCI NHI
CI
N
CI S is obtained analogously to the procedure given in example 52i) from 4-chloro-3N-(4methyl-2-benzimidazolylamino)thiophene and N-chlorosuccinimide in glacial acetic acid, with analogous work-up. Crystalline product, m.p. 296-2980C.
Example 60: trans-(3aS,7aS)-4-Chloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2benzimidazolyl)-3-thienylamine hydrochloride x HCI
NN
H
S
a) trans-S,S-3N-(2-Aminocyclohexyl)-N'-(4-chloro-3-thienyl)thiourea is obtained analogously to the reaction given in example 1, b) from 4-chloro-3-thienyl isothiocyanate and trans-S,S-1,2-diaminocyclohexane by column-chromatographic separation on silica gel using a mixture of 10 parts of ethyl acetate, 5 parts of dichloromethane, 5 parts of n-heptane, 5 parts of methanol and 1 part of ammonia as an amorphous dark product which is processed further without further work-up.
b) trans-(3aS, 7aS)-4-Chloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-3thienylamine is obtained analogously to the procedure given in example 52h) from trans-S,S-3N-(2aminocyclohexyl)-N'-(4-chloro-3-thienyl)thiourea, p-toluenesulfonyl chloride and subsequent application of medium pressure column chromatography on silica gel using a mixture of 10 parts of dichloromethane and 1 part of methanol, as an amorphous, foam-like product. Preparation of the trans-S,S-4-chloro-3N- (3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-3-thienylamine hydrochloride in ethyl acetate and a little ethanol using diethyl ether saturated with hydrogen chloride gas.
Crystalline product, m.p. 196-200 0
C.
Example 61: trans-(3aR,7aR)-4-Chloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2benzimidazolyl)-3-thienylamine hydrochloride x HCI N H
H
S
a) trans-(1 R,2R)-3N-(2-Aminocyclohexyl)-N'-(4-chloro-3-thienyl)thiourea is obtained analogously to the reaction given in example 1, b) from 4-chloro-3-thienyl isothiocyanate and trans-(1R,2R)-(-)-1,2-diaminocyclohexane by subsequent columnchromatographic separation on silica gel using a mixture of 10 parts of ethyl acetate, parts of n-heptane, 5 parts of dichloromethane, 5 parts of methanol and 1 part of ammonia as an amorphous, dark product which is processed further without further work-up.
b) trans-(3aR, 7aR)-4-Chloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-3thienylamine is obtained analogously to the procedure given in example 52h) from trans-R,R-3N-(2aminocyclohexyl)-N'-(4-chloro-3-thienyl)thiourea, p-toluenesulfonyl chloride and subsequent application of medium pressure column chromatography on silica gel using a mixture of 10 parts of ethyl acetate, 5 parts of n-heptane, 5 parts of dichloromethane, 5 parts of methanol and 1 part of ammonia as an amorphous, oily product. Preparation of the trans-R,R-4-chloro-3N-(3a,4,5,6,7,7ahexahydro-1 H-2-benzimidazolyl)-3-thienylamine hydrochloride in ethyl acetate and a little ethanol using diethyl ether saturated with hydrogen chloride gas. Crystalline product, m.p. 240-244 0
C.
Example 62: cis-4-Chloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-3thienylamine hydrochloride H xHCI H
CI
>N
NC
H
H
S
a) cis-3N-(2-Aminocyclohexyl)-N'-(4-chloro-3-thienyl)thiourea is obtained analogously to the reaction given in example 1, b) from 4-chloro-3-thienyl isothiocyanate and cis-1,2-diaminocyclohexane by subsequent columnchromatographic separation on silica gel using a mixture of 10 parts of ethyl acetate, parts of n-heptane, 5 parts of dichloromethane, 5 parts of methanol and 1 part of ammonia as an amorphous, dark product which is processed further without further work-up.
b) cis-4-Chloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-3-thienylamine is obtained analogously to the procedure given in example 52h) from 3N-(cis-2-aminocyclohexyl)-N'-(4-chloro-3-thienyl)thiourea, p-toluenesulfonyl chloride and subsequent application of medium pressure column chromatography on silica gel using a mixture of 10 parts of ethyl acetate, 5 parts of n-heptane, 5 parts of dichloromethane, 5 parts of methanol and 1 part of ammonia as a brown, oily product. Preparation of the 4-chloro-3N-(cis-3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-3-thienylamine hydrochloride in ethyl acetate and a little ethanol, using diethyl ether saturated with hydrogen chloride gas. Crystalline product, m.p. 228-231C.
Example 63: trans-R,R-2,4-Dichloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-benzimidazolyl) 3-thienylamine hydrochloride x HCI rN H cl
N
H
CI S is obtained analogously to the procedure given in example 52i) by reacting trans-R,R- 4-chloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-3-thienylamine with N-chlorosuccinimide and analogous work-up. Crystalline product. Foaming with sublimation starting at 1650C.
Example 64: cis-2,4-Dichloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-3thienylamine hydrochloride H xHCI QH
CI
_N
INI
H
H
CI S is obtained analogously to the procedure given in example 52i) by reacting cis-4chloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-3-thienylamine with N-chlorosuccinimide and analogous work-up. Crystalline product. M.p. 270-274*C.
Example 65: 4-Chloro-3N-(4-chloro-2-benzimidazolylamino)thiophene hydrochloride Cl x HCI
H
S
a) 1-N-(2-Amino-3-chlorophenyl)-3-N-(4-chloro-3-thienyl)thiourea is obtained from 3-chloro-1,2-diaminobenzene and 4-chloro-3-thienyl isothiocyanate analogously to the procedure described in example Ib) and crystallization under diisopropyl ether, as a solid having two melting points: m.p. 1: 152-155°C with recrystallization; m.p. 2: >310°C b) 4-Chloro-3N-(4-chloro-2-benzimidazolylamino)thiophene is obtained analogously to the procedure described in example 52h) by reacting 1-N- (2-amino-3-chlorophenyl)-3-N-(4-chloro-3-thienyl)thiourea with p-toluenesulfonyl chloride and column chromatography on silica gel using a mixture of 3 parts of toluene and 1 part of ethyl acetate as mobile phase and subsequent distillative removal of the solvent under reduced pressure, as a foam-like, amorphous product which is converted further into the hydrochloride.
c) 4-Chloro-3N-(4-chloro-2-benzimidazolylamino)thiophene hydrochloride is obtained by treating a solution of 4-chloro-3N-(4-chloro-2benzimidazolylamino)thiophene in ethyl acetate with a solution in diethyl ether saturated with hydrogen chloride gas, as a crystalline precipitate. M.p. 276-280 0
C.
Example 66: 2 ,4-Dichloro-3N-(4-chloro-2-benzimidazolylamino)thiophene hydrochloride Cl x HCI
H
Cl S is obtained analogously to the procedure given in example 52i) from 4-chloro-3N-(4methyl-2-benzimidazolylamino)thiophene and N-chlorosuccinimide in glacial acetic acid, with analogous work-up. Crystalline product, m.p. 294-297*C.
Analogously to the compounds listed in the working examples, it is possible to prepare the following thiophene derivatives: 2-bromo-4-chloro-3N-(4-methyl-2-benzimidazolylamino)thiophene hydrochloride, m.p. 284-286*C, 2-bromo-4-chloro-3N-(4-chloro-2-benzimidazolylamino)thiophene hydrochloride, m.p. 304-306*C, trans-R,R-2-bromo-4-chloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-3thienylamine hydrochloride, point of decomposition: 21 trans-(3aS ,7aS)-2-bromo-4-chloro-3N-(3a,4,5,6,7,7a-hexahyd ro-1 H-2-benzimidazolyl)- 3-thienylamine hydrochloride 243-254 0
C,
2,4-d ibromo-3 N-(2-benzi mid azolyl)-3-th ie nyl am ine hydrochloride, 2,4-d imethyl-3N-(2-benzimidazolyl)-3-thienylamine hydrochloride, 2 ,4-dimethyl-3N-(4-methyl-2-benzimidazolyl)-3-thienylamine hydrochloride, 2,4-dimethyl-3N-(5-fluoro-2-benzimidazolyl)-3-thienylamine hydrochloride, 2-chloro-3N-(4-butoxy-2-benzimidazolyl)-4-methyl-3-thienylamine hydrochloride, 2-chloro-3N-(4-trifluoromethyl-2-benzimidazolyl )-4-methyl-3-thienylamine hydrochloride, 2-chloro-3N-(4-methylsulfonyl-2-benzimidazolyl )-4-methyl-3-thienylamine hydrochloride.
Pharmacological data: Test description: In this test, the recovery of the intracellular pH (pHi) after an acidification, which starts when the NHE is capable of functioning, even under bicarbonate-free conditions, was determined. For this purpose, the pHi was determined using the pH-sensitive fluorescent dye BCECF (Calbiochem, the precursor BCECF-AM is employed). The cells were initially loaded with BCECF. The BCECF fluorescence was determined in a "ratio fluorescence spectrometer" (Photon Technology International, South Brunswick, USA) with excitation wavelengths of 505 and 440 nm and an emission wavelength of 535 nm, and was converted into the pHi using calibration plots. The cells were incubated in NH 4 CI buffer (pH 7.4) (NH 4 CI buffer: 115 mM NaCI, 20 mM
NH
4 CI, 5 mM KCI, 1 mM CaCI2, 1 mM MgSO4, 20 mM Hepes, 5 mM glucose, 1 mg/ml BSA; a pH of 7.4 is established with 1 M NaOH) even during the BCECF loading. The intracellular acidification was induced by addition of 975 pl of an NH 4 CI-free buffer (see below) to 25 pl aliquots of the cells incubated in NH 4 CI buffer. The subsequent rate of pH recovery was recorded in the case of NHE1 for two minutes, in the case of NHE2 for five minutes and in the case of NHE3 for three minutes. To calculate the inhibitory power of the tested substances, the cells were initially investigated in buffers in which complete or absolutely no pH recovery took place. For complete pH recovery (100%), the cells were incubated in Na'-containing buffer (133.8 mM NaCI, 4.7 mM KCI, 1.25 mM CaCI2, 1.25 mM MgCI2, 0.97 mM Na 2 HPO4, 0.23 mM NaH 2
PO
4 5 mM Hepes, 5 mM glucose, a pH of 7.0 is established with 1 M NaOH). To determine the 0% value, the cells were incubated in an Na+-free buffer (133.8 mM choline chloride, 4.7 mM KCI, 1.25 mM CaCI2, 1.25 mM MgCI2, 0.97 mM K 2
HPO
4 0.23 mM KH 2
PO
4 mM Hepes, 5 mM glucose, a pH of 7.0 is established with 1 M KOH). The substances to be tested were made up in the Na+-containing buffer. Recovery of the intracellular pH at each tested concentration of a substance was expressed as a percentage of the maximum recovery. Using the Sigma-Plot program, the IC50 value of the substance in question was calculated for the individual NHE subtypes using the percentages for pH recovery.
Results: Example
IC
50 [pJM], 16 trans-R, R-2-chloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2- 0.27 (rNH E3) benzimidazolyl )-4-methyl-3-thienylamine hydrochloride 12 2-chloro-3N-(2-benzimidazolyl)-4-methyl-3-thienylamine 0.12 (rN HE3) hydrochloride 54: 2-bromo-4-chloro-3N-(2-benzimidazolylamino)thiophene 0.22 (h NHE3) hydrochloride 53: 2 ,4-d ichloro-3N-(2-benzimidazolylamino)thiophene 0.14 (hN HE3) hydrochloride 56: 2,4-d ichloro-3 N-(4-methyl-2-benzi mid azolyl- 0.22 (h NHE3) amino)thiophene hydrochloride trans-R,R-2,4-dichloro-3N-(3a,4 ,5,6,7 ,7a-hexahydro-1 H- 0.19 (hNHE3) 2-benzimidazolyl)-3-thienylamine hydrochloride 63: 2 ,4-dichloro-3N-(4-chloro-2-benzimidazolyl- 0.54 (h N HE3) amino)thiophene hydrochloride 38: 2-chloro-3N-(4-hyd roxy-2-benzimidazolylamino)-4- 0.84 (hN HE3) methylthiophene hydrochloride 18: 2-b romo-3 N-(2-benzi mid azolyl)-4-methyl-3-th ienyla m ine 0.12 (h N HE3) hydrochloride 19: trans-R, R-2-bromo-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2- 0.56 (hNHE3) benzimidazolyl)-4-methyl-3-thienylamine hydrochloride 2: 2-chloro-3N-(5-fluoro-2-benzimidazolyl )-4-methyl-3- 0.62 (h NHE3) thienylamine hydrochloride 44: (1 H-benzimidazol-2-yI)-(2-chloro-4-methylthiophen-3-y)- 1.59 (h NH E3) methylamine
Claims (15)
1. A compound of the formula I, R3 R5 R7 N S R8 N' N R6 .R1 R4 H I in which: R1 and R2 independently of one another are H, F, CI, Br, I, CN, NO 2 -(X)n-CqH2q-Z, cycloalkyl having 3, 4, 5 or 6 carbon atoms, alkenyl having 2, 3 or 4 carbon atoms, alkenylalkyl having 3 or 4 carbon atoms, ethynyl or alkylalkynyl having 3 or 4 carbon atoms; n is zero or 1; X is oxygen, NH, N-CH 3 or S(O)K; k is zero,.1 or 2; q is zero, 1,2, 3, 4, 5 or 6; Z is hydrogen or CmF2m+l; m is zero, 1,2, 3 or 4; R3 is hydrogen, methyl, F, CI, Br, I, CN, S(O)k-CH3, -NO 2 or-O-CH 3 k is zero, 1 or 2; R4 is hydrogen, cycloalkyl having 3, 4, 5, or 6 carbon atoms, alkenyl having 2, 3 or 4 carbon atoms, alkenylalkyl having 3 or 4 carbon atoms, ethynyl or alkylalkynyl having 3 or 4 carbon atoms, or -CrH2r- Y; r is zero, 1, 2, 3 or 4; Y is hydrogen or trifluoromethyl; and R6 are hydrogen or together are a bond; R7 and R8 independently of one another are (C3-C5)-alkyl, (C2-C5)-alkenyl, alkynyl, (C3-C6)-cycloalkyl or (C4-C6)-cycloalkenyl or R7 and R8 together are an alkylene chain comprising 3 to 8 carbon atoms; where none, some or all of their hydrogen atoms may be replaced by fluorine atoms; or R7 and R8 together are a radical R12 R11 R9 where R5 and R6 together form a bond; R10 and R11 independently of one another are hydrogen, fluorine, chlorine, bromine, methyl, CN, OH, -O-CH 3 NO 2 NH 2 or -CF 3 R9 and R12 are hydrogen or F; or one of the substituents R9 and R12 is hydrogen; and the other is F, CI, Br, I, CN, N02, COOH, CO-NR13R14, SO 2 NR13R14, alkenyl having 2, 3 or 4 carbon atoms, alkenylalkyl having 3 or 4 carbon atoms, ethynyl, alkylalkynyl having 3 or 4 carbon atoms or CqH2q-Z; 78 00 SR13 and R14 C are identical or different hydrogen or alkyl having 1, 2, 3 or 4 carbon atoms; O or 0 5 R13 and R14 together with the nitrogen to which they are attached form a saturated 6- or 7-membered ring; n is zero or 1; X is oxygen, NH, N-CH 3 S(O)k; c k is zero, 1 or 2; r 10 q is zero, 1, 2, 3, 4, 5 or 6; and CN Z is hydrogen or CmF2m+1; m is zero, 1, 2, 3 or 4; and its pharmaceutically acceptable salts, and its trifluoroacetic acid salts.
2. A compound as claimed in claim 1, in which: R1 and R2 independently of one another are H, F, CI, Br, CH 3 CF 3 or SO2CH 3 but where at most one of the substituents R1 and R2 is hydrogen; R3 is hydrogen, F or Cl; R4 is hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms, or cyclopropyl; and R6 are hydrogen or together are a bond; R7 and R8 together are an alkylene chain comprising 3, 4, 5, 6, 7 or 8 carbon atoms; or R7 and R8 together are a radical 79 R12 R11 R9 where R5 and R6 together form a bond; and R11 independently of one another are hydrogen, OH, fluorine or chlorine; R9 and R12 are hydrogen; or one of the substituents R9 and R12 is hydrogen; and the other is F, Cl, Br, CN, COOH, CO-NR13R14, SO2-NR13R14 or CqH2q-Z; R13 and R14 are identical or different hydrogen or methyl; n is zero or 1; X is oxygen, NH, N-CH 3 or S(O)k; k is zero, 1 or 2; q is zero, 1, 2, 3 or 4; Z is hydrogen or CF3; and its pharmaceutically acceptable salts, and its trifluoroacetic acid salts.
3. A compound as claimed in claim 1 and/or 2, in which: R1 and R2 independently of one another are F, Cl, Br, CH 3 or CF 3 R3 is hydrogen; R4 is hydrogen, methyl, ethyl; and R6 are hydrogen or together are a bond; R7 and R8 together are an alkylene chain comprising 3, 4, 5, 6, 7 or 8 carbon atoms; or R7 and R8 together are a radical R12 R11 R9 where R5 and R6 together form a bond; and R11 independently of one another are hydrogen, OH or fluorine; R9 and R12 are hydrogen; or one of the substituents R9 and R12 is hydrogen; and the other is F, Cl, Br or CqH2q-Z; n is zero or 1; X is oxygen, NH, N-CH3 or S(O)k; k is zero, 1 or 2; q is zero or 1; Z is hydrogen or CF 3 and its pharmaceutically acceptable salts, and its trifluoroacetic acid salts.
4. A compound of the formula I as claimed in one or more of claims 1, 2 and 3, selected from the group consisting of: trans-R,R-2-chlorine-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-4-methyl-3- thienylamine, trans-R, R-2-bromo-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-4-methyl-3- thienylamine, 2-chloro-3N-(2-benzimidazolyl)-4-methyl-3-thienylamine, 2-bromo-3 N-(2-benzi mid azolyl)-4-methyl-3-th ienyla m ine, 2-chloro-3N-(4-methyl-2-benzimidazolyl)-4-methyl-3-thienylamine, 2-chloro-3N-(5-fluoro-2-benzimidazolyl)-4-methyl-3-thienylamine, 2-chloro-3N-(4-chloro-2-benzimidazolylamino)-4-methylthiophene, 2-b romo-3 N-(4-ch loro-2-benzi mid azolylam ino)-4-methylth io phen e, 2-bromo-3N-(4-fluoro-2-benzimidazolylamino)-4-methylthiophene, 2-chloro-3N-(4-fluoro-2-benzimidazolylamino)-4-methylthiophene, 2-chloro-3N-(4-hydroxy-2-benzimidazolylamino)-4-methylthiophene, (1 H-benzimidazol-2-yl)-(2-chloro-4-methylthiophen-3-yl)-methylamine, (2-bromo-4-methylthiophen-3-y)-(5-fluoro-1 H-benzimidazol-2-yl)-amine, 2-chloro-3N-(2-benzimidazolylamino).-4-methylthiophene, 2,4-dichloro-3N-(2-benzimidazolylamino)thiophene, 2-bromo-4-chloro-3N-(2-benzimidazolylamino)thiophene, 2,4-dichloro-3N-(4-methyl-2-benzimidazolylamino)thiophene, trans-R, R-2 ,4-dichloro-3N-(3a,4,5,6,7,7a-hexahydro-1 H-2-benzimidazolyl)-3- thienylamine, and 2,4-dichloro-3N-(4-chloro-2-benzimidazolylamino)thiophene and their pharmaceutically acceptable salts.
A compound of the formula I and/or a pharmaceutically acceptable salt thereof as claimed in one or more of claims 1 to 4 for use as a med icament.
6. The use of a compound of the formula I and/or a pharmaceutically acceptable salt thereof as claimed in one or more of claims 1 to 4 for preparing a medicament for the treatment or prophylaxis of respiratory disorders, in particular respiratory disorders associated with sleeping, such as sleep apnea, or of snoring, for the treatment or prophylaxis of acute and chronic renal diseases, in particular acute kidney failure or chronic kidney failure, or of disorders of intestinal function, for the treatment or prophylaxis of high blood pressure, in particular essential hypertension, of disorders of the central nervous system, in particular disorders which are the result of CNS overexcitability, such as epilepsy or centrally induced spasms, and of disorders of the central nervous system, in particular states of anxiety, depressions and psychoses, for the treatment or prophylaxis of acute and chronic damage and disorders of organs or tissue caused by ischemic events or by reperfusion events and indirect sequelae thereof, of arrhythmias, of atherosclerosis, of hypercholesterolemia, of diseases in which cell proliferation is a primary or secondary cause, of cancer, of prostate hypertrophy or prostate hyperplasia, of fibrotic disorders of internal organs, of cardiac insufficiency or of congestive heart failure, of thromboses, of disorders of gall function, of infection by ectoparasites, of disorders which are the result of endothelial dysfunction, of intermittent claudication, of protozoa disorders, in particular malaria, for the treatment of states of shock, diabetes and late diabetic damage, acute or chronic inflammatory disorders or for preparing a medicament for the preservation and storage of transplants for surgical interventions, for preparing a medicament for use in surgical operations and organ transplantations, for preparing a medicament for preventing age-related tissue change, for maintaining health and prolonging life, for reducing cytotoxic effects or for use as diagnostics.
7. The use of a compound of the formula I and/or a pharmaceutically acceptable salt thereof as claimed in one or more of claims 1 to 4 in combination with other drugs or active compounds for preparing a medicament for the treatment or prophylaxis of respiratory disorders, in particular respiratory disorders associated with sleeping, such as sleep apnea, or of snoring, for the treatment or prophylaxis of acute and chronic renal diseases, in particular acute kidney failure or chronic kidney failure, or of disorders of intestinal function, for the treatment or prophylaxis of high blood pressure, in particular essential hypertension, of disorders of the central nervous system, in particular disorders which are the result of CNS overexcitability, such as epilepsy or centrally induced spasms, and of disorders of the central nervous system, in particular states of anxiety, depressions and psychoses, for the treatment or prophylaxis of acute and chronic damage and disorders of organs or tissues caused by ischemic events or by reperfusion events and indirect sequelae thereof, of arrhythmias, of atherosclerosis, of hypercholesterolemia, of diseases in which cell proliferation is a primary or secondary cause, of cancer, of prostate hypertrophy or prostate hyperplasia, of fibrotic disorders of internal organs, of cardiac insufficiency or of congestive heart failure, of thromboses, of disorders of gall function, of infection by ectoparasites, of disorders which are the result of endothelial dysfunction, of intermittent claudication, of protozoa disorders, in particular malaria, for the treatment of states of shock, diabetes and late diabetic damage, acute or chronic inflammatory disorders or for preparing a medicament for the preservation and storage of transplants for surgical interventions, for preparing a medicament for use in surgical operations and organ transplantations, for preparing a medicament for preventing age-related tissue change, for maintaining health and prolonging life or for reducing cytotoxic effects.
8. The use of a compound of the formula I and/or a pharmaceutically acceptable salt thereof as claimed in one or more of claims 1 to 4 alone or in combination with other drugs or active compounds for preparing a medicament for the treatment or prophylaxis of respiratory disorders, in particular respiratory disorders associated with sleeping, such as sleep apnea.
9. The use of a compound of the formula I and/or a pharmaceutically acceptable salt thereof as claimed in one or more of claims 1 to 4 alone or in combination with other drugs or active compounds for preparing a medicament for the treatment of prophylaxis or snoring.
The use of a compound of the formula I and/or a pharmaceutically acceptable salt thereof as claimed in one or more of claims 1 to 4 alone or in combination with other drugs or active compounds for preparing a medicament for the treatment or prophylaxis of acute and chronic renal diseases, in particular acute kidney failure or chronic kidney failure.
11. The use of a compound of the formula I and/or a pharmaceutically acceptable salt thereof as claimed in one or more of claims 1 to 4 alone or in combination with other 84 00 0 drugs or active compounds for preparing a medicament for the treatment or prophylaxis 0 O Z
12. A medicament for human, veterinary or phytoprotective use, comprising an S 5 effective amount of a compound of the formula I and/or a pharmaceutically acceptable salt thereof as claimed in one or more of claims 1 to 4, together with pharmaceutically Sacceptable carriers and additives.
S13. A medicament for human, veterinary or phytoprotective use, comprising an C 10 effective amount of a compound of the formula I and/or a pharmaceutically acceptable Ssalt thereof as claimed in one or more of claims 1 to 4, together with pharmaceutically ri acceptable carriers and additives, in combination with other pharmacologically active compounds or drugs.
14. A method of medical treatment or prophylaxis of a disorder described in claim 6 by the administration of an effective amount of a compound of the formula I and/or pharmaceutically acceptable salt thereof claimed in one or more of claims 1 to 4 to a subject in need.
15. A compound of the formula I and/or a pharmaceutically acceptable salt thereof as claimed in one or more of claims 1 to 4 substantially as hereinbefore described. SANOFI-AVENTIS DEUTSCHLAND GMBH WATERMARK PATENT TRADE MARK ATTORNEYS P24848AU00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10224892.3 | 2002-06-04 | ||
DE10224892A DE10224892A1 (en) | 2002-06-04 | 2002-06-04 | Substituted thiophenes, process for their preparation, their use as a medicament or diagnostic agent, and medicament containing them |
PCT/EP2003/005465 WO2003101984A1 (en) | 2002-06-04 | 2003-05-26 | Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003273553A1 AU2003273553A1 (en) | 2003-12-19 |
AU2003273553B2 true AU2003273553B2 (en) | 2008-12-04 |
Family
ID=29557542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003273553A Ceased AU2003273553B2 (en) | 2002-06-04 | 2003-05-26 | Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same |
Country Status (33)
Country | Link |
---|---|
EP (1) | EP1513834B1 (en) |
JP (1) | JP4511924B2 (en) |
KR (1) | KR101087966B1 (en) |
CN (1) | CN1324024C (en) |
AR (1) | AR040239A1 (en) |
AT (1) | ATE320425T1 (en) |
AU (1) | AU2003273553B2 (en) |
BR (1) | BR0311548A (en) |
CA (1) | CA2488242C (en) |
CR (1) | CR7577A (en) |
DE (2) | DE10224892A1 (en) |
DK (1) | DK1513834T3 (en) |
EC (1) | ECSP045471A (en) |
ES (1) | ES2258722T3 (en) |
HK (1) | HK1076460A1 (en) |
HR (1) | HRP20041153A2 (en) |
IL (1) | IL165519A (en) |
MA (1) | MA27204A1 (en) |
ME (1) | MEP27608A (en) |
MX (1) | MXPA04011986A (en) |
MY (1) | MY129832A (en) |
NO (1) | NO329351B1 (en) |
OA (1) | OA12827A (en) |
PE (1) | PE20040534A1 (en) |
PL (1) | PL372589A1 (en) |
PT (1) | PT1513834E (en) |
RS (1) | RS51141B (en) |
RU (1) | RU2315766C2 (en) |
TN (1) | TNSN04240A1 (en) |
TW (1) | TWI283675B (en) |
UA (1) | UA77551C2 (en) |
WO (1) | WO2003101984A1 (en) |
ZA (1) | ZA200409095B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040242560A1 (en) | 2003-05-22 | 2004-12-02 | Aventis Pharma Deutschland Gmbh | Process for synthesizing heterocyclic compounds |
DE10323701A1 (en) | 2003-05-22 | 2004-12-23 | Aventis Pharma Deutschland Gmbh | Process for the synthesis of heterocyclic compounds |
ES2545903T3 (en) | 2003-06-30 | 2015-09-16 | Sumitomo Chemical Company, Limited | Asymmetric urea compounds and process for producing asymmetric compounds by reaction of asymmetric addition of conjugate using said compounds as catalyst |
US20100056515A1 (en) * | 2006-10-25 | 2010-03-04 | Kazuyoshi Aso | Benzimidazole compounds |
US8822449B2 (en) | 2008-09-02 | 2014-09-02 | Sanofi | Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof |
WO2011058139A1 (en) * | 2009-11-12 | 2011-05-19 | Selvita Sp. Z O. O. | A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent |
RU2518740C1 (en) * | 2013-03-22 | 2014-06-10 | Федеральное государственное автономное образовательное учреждение высшего профессионального образования "ЮЖНЫЙ ФЕДЕРАЛЬНЫЙ УНИВЕРСИТЕТ" | METHOD, INHIBITING Na+/H+-EXCHANGE, AND DIHYDROCHLORIDE OF 2-(3,4-METHYLENEDIOXYPHENYL)-9-MORPHOLINOETHYLIMIDAZO[1,2-a]BENZIMIDAZOLE |
RS58378B1 (en) | 2014-07-25 | 2019-04-30 | Taisho Pharmaceutical Co Ltd | Phenyl tetrahydroisoquinoline compound substituted with heteroaryl |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE754935A (en) | 1969-08-13 | 1971-02-17 | Hoechst Ag | 2- (THIENYL-3'-AMINO) -1,3-DIAZACYCLOALCENES AND THEIR PREPARATION |
BR6915362D0 (en) * | 1969-08-16 | 1973-01-04 | Hoechst Ag | PROCESS FOR THE PREPARATION OF 2 (TIENIL-3-AMINO) 1,3-DIAZACYCLEALCHENE |
DE2830279A1 (en) * | 1978-07-10 | 1980-01-31 | Boehringer Sohn Ingelheim | 2-CORNER CLAMP ON N- (2'-CHLOR-4'-METHYL-THIENYL-3 ') - N- (CYCLOPROPYLMETHYL) - AMINO CORNER CLAMP ON-IMIDAZOLINE- (2), THE ACID ADDITION SALTS THAT IT INCLUDES HIS PRODUCTION |
JP2002521450A (en) * | 1998-07-29 | 2002-07-16 | メルク エンド カムパニー インコーポレーテッド | Integrin receptor antagonist |
DE19960204A1 (en) * | 1999-12-14 | 2001-06-28 | Aventis Pharma Gmbh | Substituted norlbornylamino derivatives, processes for their preparation, their use as medicaments or diagnostic agents and medicaments containing them |
CA2480638C (en) * | 2002-03-29 | 2013-02-12 | Chiron Corporation | Substituted benzazoles and use thereof as raf kinase inhibitors |
-
2002
- 2002-06-04 DE DE10224892A patent/DE10224892A1/en not_active Withdrawn
-
2003
- 2003-05-26 UA UA20041211000A patent/UA77551C2/en unknown
- 2003-05-26 BR BR0311548-8A patent/BR0311548A/en not_active IP Right Cessation
- 2003-05-26 ME MEP-276/08A patent/MEP27608A/en unknown
- 2003-05-26 AT AT03740148T patent/ATE320425T1/en active
- 2003-05-26 EP EP03740148A patent/EP1513834B1/en not_active Expired - Lifetime
- 2003-05-26 AU AU2003273553A patent/AU2003273553B2/en not_active Ceased
- 2003-05-26 ES ES03740148T patent/ES2258722T3/en not_active Expired - Lifetime
- 2003-05-26 MX MXPA04011986A patent/MXPA04011986A/en active IP Right Grant
- 2003-05-26 PT PT03740148T patent/PT1513834E/en unknown
- 2003-05-26 DE DE50302673T patent/DE50302673D1/en not_active Expired - Lifetime
- 2003-05-26 JP JP2004509675A patent/JP4511924B2/en not_active Expired - Fee Related
- 2003-05-26 RS YUP-1038/04A patent/RS51141B/en unknown
- 2003-05-26 KR KR1020047019725A patent/KR101087966B1/en not_active IP Right Cessation
- 2003-05-26 RU RU2004138812/04A patent/RU2315766C2/en not_active IP Right Cessation
- 2003-05-26 CN CNB038128462A patent/CN1324024C/en not_active Expired - Fee Related
- 2003-05-26 OA OA1200400321A patent/OA12827A/en unknown
- 2003-05-26 WO PCT/EP2003/005465 patent/WO2003101984A1/en active IP Right Grant
- 2003-05-26 PL PL03372589A patent/PL372589A1/en not_active Application Discontinuation
- 2003-05-26 CA CA2488242A patent/CA2488242C/en not_active Expired - Fee Related
- 2003-05-26 DK DK03740148T patent/DK1513834T3/en active
- 2003-05-30 PE PE2003000531A patent/PE20040534A1/en not_active Application Discontinuation
- 2003-06-02 AR ARP030101958A patent/AR040239A1/en active IP Right Grant
- 2003-06-02 TW TW092114860A patent/TWI283675B/en not_active IP Right Cessation
- 2003-06-03 MY MYPI20032052A patent/MY129832A/en unknown
-
2004
- 2004-11-10 ZA ZA200409095A patent/ZA200409095B/en unknown
- 2004-11-16 MA MA27952A patent/MA27204A1/en unknown
- 2004-11-19 CR CR7577A patent/CR7577A/en unknown
- 2004-12-02 IL IL165519A patent/IL165519A/en not_active IP Right Cessation
- 2004-12-02 EC EC2004005471A patent/ECSP045471A/en unknown
- 2004-12-03 TN TNP2004000240A patent/TNSN04240A1/en unknown
- 2004-12-03 HR HR20041153A patent/HRP20041153A2/en not_active Application Discontinuation
- 2004-12-16 NO NO20045504A patent/NO329351B1/en not_active IP Right Cessation
-
2005
- 2005-09-23 HK HK05108392A patent/HK1076460A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7488746B2 (en) | Substituted thiophenes: compositions, processes of making, and uses in disease treatment and diagnosis | |
US8067614B2 (en) | N-substituted (benzoimidazol-2-yl)phenylamines, processes for their preparation, their use as a medicament or diagnostic aid, and a medicament comprising them | |
RU2272031C2 (en) | Substituted 2-anilinobenzimidazoles, their using as inhibitors of na+/h+-exchange and medicinal agent comprising thereof | |
WO2006032372A1 (en) | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, their use as a medicament, and a medicament containing them | |
AU2003273553B2 (en) | Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same | |
US8124621B2 (en) | Substituted 1-amino-4-phenyl-dihydroisoquinolines, methods for the production thereof, use thereof as a medicament, and medicaments containing them | |
US7179830B2 (en) | Substituted thienoimidazoles useful for disease treatment and prevention | |
JP4630270B2 (en) | N-substituted (benzimidazol-2-yl) phenylamines, processes for their preparation, their use as medicaments or diagnostics and medicaments containing said substances | |
US20040259927A1 (en) | Novel substituted 2-aminoimidazoles, process for their preparation, their use as medicament or diagnostic aid | |
NZ536970A (en) | Substituted thiophenes, method for the production thereof, their use as a medicament or diagnostic reagent, and a medicament containing the same | |
MX2008011589A (en) | Substituted 2-amino-4-phenyl-dî¹hydroquinolines, method for the production thereof, use thereof as medicaments, and medicaments containing them. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1 | Assignment before grant (sect. 113) |
Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH Free format text: FORMER APPLICANT(S): AVENTIS PHARMA DEUTSCHLAND GMBH |
|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |